<?xml version="1.0" encoding="UTF-8" ?><xml><records><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1760</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">1760</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Gynecological Obstetrics and Urologic Sciences, University Sapienza of Rome, Rome, Italy. lavinia.domenici@gmail.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">D-mannose: a promising support for acute urinary tract infections in women. A pilot study</style></title><secondary-title><style face="normal" font="default" size="100%">European review for medical and pharmacological sciences</style></secondary-title><short-title><style face="normal" font="default" size="100%">D-mannose: a promising support for acute urinary tract infections in women. A pilot study</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Eur Rev Med Pharmacol Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">European review for medical and pharmacological sciences</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">2920‐2925</style></pages><volume><style face="normal" font="default" size="100%">20</style></volume><number><style face="normal" font="default" size="100%">13</style></number><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1128-3602</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVE: Urinary tract infections still represent a significant bother for women and result in high costs to the health system. D‐mannose is a simple sugar; it seems able to hinder bacteria adhesion to the urothelium. The present study aimed to determine whether D‐mannose alone is effective in treating acute urinary tract infections in women and its possible utility in the management of recurrences. PATIENTS AND METHODS: This is a pilot study, performed between April 2014 and July 2015 at Department of Gynaecological Obstetrics and Urologic Sciences of &quot;Sapienza&quot; University of Rome. A D‐mannose compound was administered twice daily for 3 days and then once a day for 10 days. Changes in patients&apos; symptoms, the therapeutic effects and changes in quality of life (QoL) were evaluated clinically and using a specifically validated questionnaire (UTISA). After described treatment, patients were randomized in receiving or not prophylaxis in the next 6 months. RESULTS: Mean UTISA scores recorded after completing the treatment, compared with baseline scores, showed a significant improvement of the majority of symptoms (p &lt; 0.05). D‐mannose seemed to have had a significant positive effect on UTIs&apos; resolution and QoL improvement (p = 0.0001). As prophylactic agent administered for 6 months, it showed promising results (4.5% vs. 33.3% recurrences in treated and untreated patients respectively). CONCLUSIONS: The results of this study suggest that D‐mannose can be an effective aid in acute cystitis management and also a successful prophylactic agent in a selected population; however, more studies will certainly be needed to confirm the results of our pilot study.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Anna</style></label><notes><style face="normal" font="default" size="100%">2284-0729&#xD;Domenici, L&#xD;Monti, M&#xD;Bracchi, C&#xD;Giorgini, M&#xD;Colagiovanni, V&#xD;Muzii, L&#xD;Benedetti Panici, P&#xD;Journal Article&#xD;Italy&#xD;Eur Rev Med Pharmacol Sci. 2016 Jul;20(13):2920-5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01602700/full</style></url></related-urls></urls></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2901</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">2901</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Gynecological Obstetrics and Urologic Sciences, University Sapienza of Rome, Rome, Italy. lavinia.domenici@gmail.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">D-mannose: a promising support for acute urinary tract infections in women. A pilot study</style></title><secondary-title><style face="normal" font="default" size="100%">European review for medical and pharmacological sciences</style></secondary-title><short-title><style face="normal" font="default" size="100%">D-mannose: a promising support for acute urinary tract infections in women. A pilot study</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Eur Rev Med Pharmacol Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">European review for medical and pharmacological sciences</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">2920‐2925</style></pages><volume><style face="normal" font="default" size="100%">20</style></volume><number><style face="normal" font="default" size="100%">13</style></number><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1128-3602</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVE: Urinary tract infections still represent a significant bother for women and result in high costs to the health system. D‐mannose is a simple sugar; it seems able to hinder bacteria adhesion to the urothelium. The present study aimed to determine whether D‐mannose alone is effective in treating acute urinary tract infections in women and its possible utility in the management of recurrences. PATIENTS AND METHODS: This is a pilot study, performed between April 2014 and July 2015 at Department of Gynaecological Obstetrics and Urologic Sciences of &quot;Sapienza&quot; University of Rome. A D‐mannose compound was administered twice daily for 3 days and then once a day for 10 days. Changes in patients&apos; symptoms, the therapeutic effects and changes in quality of life (QoL) were evaluated clinically and using a specifically validated questionnaire (UTISA). After described treatment, patients were randomized in receiving or not prophylaxis in the next 6 months. RESULTS: Mean UTISA scores recorded after completing the treatment, compared with baseline scores, showed a significant improvement of the majority of symptoms (p &lt; 0.05). D‐mannose seemed to have had a significant positive effect on UTIs&apos; resolution and QoL improvement (p = 0.0001). As prophylactic agent administered for 6 months, it showed promising results (4.5% vs. 33.3% recurrences in treated and untreated patients respectively). CONCLUSIONS: The results of this study suggest that D‐mannose can be an effective aid in acute cystitis management and also a successful prophylactic agent in a selected population; however, more studies will certainly be needed to confirm the results of our pilot study.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Justin</style></label><notes><style face="normal" font="default" size="100%">2284-0729&#xD;Domenici, L&#xD;Monti, M&#xD;Bracchi, C&#xD;Giorgini, M&#xD;Colagiovanni, V&#xD;Muzii, L&#xD;Benedetti Panici, P&#xD;Journal Article&#xD;Italy&#xD;Eur Rev Med Pharmacol Sci. 2016 Jul;20(13):2920-5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01602700/full</style></url></related-urls></urls></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1790</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">1790</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Banks, J. C.</style></author><author><style face="normal" font="default" size="100%">Howie, J. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of General Practice, University of Edinburgh.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reducing consultations for symptoms of cystitis using a health education leaflet</style></title><secondary-title><style face="normal" font="default" size="100%">Br J Gen Pract</style></secondary-title><short-title><style face="normal" font="default" size="100%">Reducing consultations for symptoms of cystitis using a health education leaflet</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Br J Gen Pract</style></full-title><abbr-1><style face="normal" font="default" size="100%">The British journal of general practice : the journal of the Royal College of General Practitioners</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">1595-1596</style></pages><volume><style face="normal" font="default" size="100%">48</style></volume><number><style face="normal" font="default" size="100%">434</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Cystitis/*prevention &amp; control/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Family Practice</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Health Education</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Pamphlets</style></keyword><keyword><style face="normal" font="default" size="100%">*Patient Acceptance of Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">United Kingdom</style></keyword><keyword><style face="normal" font="default" size="100%">Women&apos;s Health</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1998</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0960-1643 (Print)&#xD;0960-1643</style></isbn><abstract><style face="normal" font="default" size="100%">This study aims to evaluate the effects of a health education leaflet on the number of general practice consultations for the symptoms of cystitis. Seventy women with symptoms of cystitis were recruited into two groups, only one group received health education leaflets. Twenty-nine per cent of patients who received leaflets re-consulted within 40 weeks from presentation compared with 66% of patients who did not receive leaflets (P &lt; 0.005).</style></abstract><label><style face="normal" font="default" size="100%">Yes - Anna</style></label><notes><style face="normal" font="default" size="100%">Banks, J C&#xD;Howie, J G&#xD;Clinical Trial&#xD;Journal Article&#xD;England&#xD;Br J Gen Pract. 1998 Sep;48(434):1595-6.</style></notes><urls></urls></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2904</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">2904</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Banks, J. C.</style></author><author><style face="normal" font="default" size="100%">Howie, J. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of General Practice, University of Edinburgh.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reducing consultations for symptoms of cystitis using a health education leaflet</style></title><secondary-title><style face="normal" font="default" size="100%">Br J Gen Pract</style></secondary-title><short-title><style face="normal" font="default" size="100%">Reducing consultations for symptoms of cystitis using a health education leaflet</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Br J Gen Pract</style></full-title><abbr-1><style face="normal" font="default" size="100%">The British journal of general practice : the journal of the Royal College of General Practitioners</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">1595-1596</style></pages><volume><style face="normal" font="default" size="100%">48</style></volume><number><style face="normal" font="default" size="100%">434</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Cystitis/*prevention &amp; control/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Family Practice</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Health Education</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Pamphlets</style></keyword><keyword><style face="normal" font="default" size="100%">*Patient Acceptance of Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">United Kingdom</style></keyword><keyword><style face="normal" font="default" size="100%">Women&apos;s Health</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1998</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0960-1643 (Print)&#xD;0960-1643</style></isbn><abstract><style face="normal" font="default" size="100%">This study aims to evaluate the effects of a health education leaflet on the number of general practice consultations for the symptoms of cystitis. Seventy women with symptoms of cystitis were recruited into two groups, only one group received health education leaflets. Twenty-nine per cent of patients who received leaflets re-consulted within 40 weeks from presentation compared with 66% of patients who did not receive leaflets (P &lt; 0.005).</style></abstract><label><style face="normal" font="default" size="100%">Yes - Justin</style></label><notes><style face="normal" font="default" size="100%">Banks, J C&#xD;Howie, J G&#xD;Clinical Trial&#xD;Journal Article&#xD;England&#xD;Br J Gen Pract. 1998 Sep;48(434):1595-6.</style></notes><urls></urls></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1875</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">1875</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dani, C.</style></author><author><style face="normal" font="default" size="100%">Biadaioli, R.</style></author><author><style face="normal" font="default" size="100%">Bertini, G.</style></author><author><style face="normal" font="default" size="100%">Martelli, E.</style></author><author><style face="normal" font="default" size="100%">Rubaltelli, F. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Surgical and Medical Critical Care, Division of Neonatology, Careggi University Hospital, Florence, Italy. cdani@unifi.it</style></auth-address><titles><title><style face="normal" font="default" size="100%">Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants. A prospective double-blind study</style></title><secondary-title><style face="normal" font="default" size="100%">Biol Neonate</style></secondary-title><short-title><style face="normal" font="default" size="100%">Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants. A prospective double-blind study</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Biol Neonate</style></full-title><abbr-1><style face="normal" font="default" size="100%">Biology of the neonate</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">103-108</style></pages><volume><style face="normal" font="default" size="100%">82</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bacterial Infections/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Dietary Supplements</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Enterocolitis, Necrotizing/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">*Infant, Premature</style></keyword><keyword><style face="normal" font="default" size="100%">*Lactobacillus</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics/administration &amp; dosage/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Failure</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/*prevention &amp; control</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2002</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0006-3126 (Print)&#xD;0006-3126</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND: It has been suggested that probiotics can reduce the overgrowth of pathogens in the bowels of preterm infants and contribute to the reduction of the incidence of nosocomial infections in neonatal intensive care units (NICUs). The purpose of this study was to evaluate the effectiveness of Lactobacillus GG supplementation in reducing the incidence of urinary tract infections (UTIs), bacterial sepsis and necrotizing enterocolitis (NEC) in preterm infants. METHODS: A double-blind study was conducted in 12 Italian NICUs. Newborn infants with a gestational age &lt;33 weeks or birthweight &lt;1,500 g were randomized to receive standard milk feed supplemented with Lactobacillus GG (Dicoflor), Dicofarm, Rome, Italy) in a dose of 6 x 10(9) colony-forming units (cfu) once a day until discharge, starting with the first feed or placebo. RESULTS: Five hundred eighty-five patients were studied. The probiotics group (n = 295) and the placebo group (n = 290) exhibited similar clinical characteristics. The duration of Lactobacillus GG and placebo supplementation was 47.3 +/- 26.0 and 48.2 +/- 24.3 days, respectively. Although UTIs (3.4 vs. 5.8%) and NEC (1.4 vs. 2.7%) were found less frequently in the probiotic group compared to the control group, these differences were not significant. Bacterial sepsis was more frequent in the probiotics group (4.4%, n = 11) than in the placebo group (3.8%, n = 9), but the difference was not significant. CONCLUSION: Seven days of Lactobacillus GG supplementation starting with the first feed is not effective in reducing the incidence of UTIs, NEC and sepsis in preterm infants. Further studies are required to confirm our results in lower birthweight populations.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Anna</style></label><notes><style face="normal" font="default" size="100%">Dani, Carlo&#xD;Biadaioli, Roberto&#xD;Bertini, Giovanna&#xD;Martelli, Elena&#xD;Rubaltelli, Firmino F&#xD;Clinical Trial&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Switzerland</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1159/000063096.</style></electronic-resource-num></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2915</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">2915</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dani, C.</style></author><author><style face="normal" font="default" size="100%">Biadaioli, R.</style></author><author><style face="normal" font="default" size="100%">Bertini, G.</style></author><author><style face="normal" font="default" size="100%">Martelli, E.</style></author><author><style face="normal" font="default" size="100%">Rubaltelli, F. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Surgical and Medical Critical Care, Division of Neonatology, Careggi University Hospital, Florence, Italy. cdani@unifi.it</style></auth-address><titles><title><style face="normal" font="default" size="100%">Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants. A prospective double-blind study</style></title><secondary-title><style face="normal" font="default" size="100%">Biol Neonate</style></secondary-title><short-title><style face="normal" font="default" size="100%">Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants. A prospective double-blind study</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Biol Neonate</style></full-title><abbr-1><style face="normal" font="default" size="100%">Biology of the neonate</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">103-108</style></pages><volume><style face="normal" font="default" size="100%">82</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bacterial Infections/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Dietary Supplements</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Enterocolitis, Necrotizing/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">*Infant, Premature</style></keyword><keyword><style face="normal" font="default" size="100%">*Lactobacillus</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics/administration &amp; dosage/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Failure</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/*prevention &amp; control</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2002</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0006-3126 (Print)&#xD;0006-3126</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND: It has been suggested that probiotics can reduce the overgrowth of pathogens in the bowels of preterm infants and contribute to the reduction of the incidence of nosocomial infections in neonatal intensive care units (NICUs). The purpose of this study was to evaluate the effectiveness of Lactobacillus GG supplementation in reducing the incidence of urinary tract infections (UTIs), bacterial sepsis and necrotizing enterocolitis (NEC) in preterm infants. METHODS: A double-blind study was conducted in 12 Italian NICUs. Newborn infants with a gestational age &lt;33 weeks or birthweight &lt;1,500 g were randomized to receive standard milk feed supplemented with Lactobacillus GG (Dicoflor), Dicofarm, Rome, Italy) in a dose of 6 x 10(9) colony-forming units (cfu) once a day until discharge, starting with the first feed or placebo. RESULTS: Five hundred eighty-five patients were studied. The probiotics group (n = 295) and the placebo group (n = 290) exhibited similar clinical characteristics. The duration of Lactobacillus GG and placebo supplementation was 47.3 +/- 26.0 and 48.2 +/- 24.3 days, respectively. Although UTIs (3.4 vs. 5.8%) and NEC (1.4 vs. 2.7%) were found less frequently in the probiotic group compared to the control group, these differences were not significant. Bacterial sepsis was more frequent in the probiotics group (4.4%, n = 11) than in the placebo group (3.8%, n = 9), but the difference was not significant. CONCLUSION: Seven days of Lactobacillus GG supplementation starting with the first feed is not effective in reducing the incidence of UTIs, NEC and sepsis in preterm infants. Further studies are required to confirm our results in lower birthweight populations.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Justin</style></label><notes><style face="normal" font="default" size="100%">Dani, Carlo&#xD;Biadaioli, Roberto&#xD;Bertini, Giovanna&#xD;Martelli, Elena&#xD;Rubaltelli, Firmino F&#xD;Clinical Trial&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Switzerland</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1159/000063096.</style></electronic-resource-num></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1889</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">1889</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eckford, S. D.</style></author><author><style face="normal" font="default" size="100%">Keane, D. P.</style></author><author><style face="normal" font="default" size="100%">Lamond, E.</style></author><author><style face="normal" font="default" size="100%">Jackson, S. R.</style></author><author><style face="normal" font="default" size="100%">Abrams, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Bristol Urological Institute, Southmead Hospital, Bristol, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hydration monitoring in the prevention of recurrent idiopathic urinary tract infections in pre-menopausal women</style></title><secondary-title><style face="normal" font="default" size="100%">Br J Urol</style></secondary-title><short-title><style face="normal" font="default" size="100%">Hydration monitoring in the prevention of recurrent idiopathic urinary tract infections in pre-menopausal women</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Br J Urol</style></full-title><abbr-1><style face="normal" font="default" size="100%">British journal of urology</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">90-93</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Drinking</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Monitoring, Ambulatory/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Osmolar Concentration</style></keyword><keyword><style face="normal" font="default" size="100%">*Premenopause</style></keyword><keyword><style face="normal" font="default" size="100%">*Reagent Strips</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">Specific Gravity</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/diagnosis/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Urination</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1995</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0007-1331 (Print)&#xD;0007-1331</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To assess whether the use of simple hydration monitoring can encourage adequate hydration and reduce urinary osmolality and the incidence of urinary tract infections (UTIs) in a population of susceptible pre-menopausal women with recurrent idiopathic urinary infections. SUBJECTS AND METHODS: The study included 28 pre-menopausal women who had at least two idiopathic UTIs in the previous 6 months. Urinary osmolality was assessed by the patients at each void by a simple hand-held probe, and the readings over 4 months compared. Monthly urine culture was compared between successive 4-month periods in which the probe was or was not used. RESULTS: The study was completed by 17 women. There was a significant shift towards urine of lower osmolality over the 4-month period using the probe (Pearson&apos;s chi 2 &lt; 0.001). Significantly fewer urinary tract infections developed during the 4 months using the probe (McNemar&apos;s chi 2 = 0.046). CONCLUSIONS: The use of the osmolality probe encouraged the subject to maintain adequate hydration. The resulting augmentation of the natural urethral &apos;washout&apos; mechanism led to lower osmolality urine and a reduction in the incidence of UTIs.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Anna</style></label><notes><style face="normal" font="default" size="100%">Eckford, S D&#xD;Keane, D P&#xD;Lamond, E&#xD;Jackson, S R&#xD;Abrams, P&#xD;Clinical Trial&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;England&#xD;Br J Urol. 1995 Jul;76(1):90-3.</style></notes><urls></urls></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2917</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">2917</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eckford, S. D.</style></author><author><style face="normal" font="default" size="100%">Keane, D. P.</style></author><author><style face="normal" font="default" size="100%">Lamond, E.</style></author><author><style face="normal" font="default" size="100%">Jackson, S. R.</style></author><author><style face="normal" font="default" size="100%">Abrams, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Bristol Urological Institute, Southmead Hospital, Bristol, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hydration monitoring in the prevention of recurrent idiopathic urinary tract infections in pre-menopausal women</style></title><secondary-title><style face="normal" font="default" size="100%">Br J Urol</style></secondary-title><short-title><style face="normal" font="default" size="100%">Hydration monitoring in the prevention of recurrent idiopathic urinary tract infections in pre-menopausal women</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Br J Urol</style></full-title><abbr-1><style face="normal" font="default" size="100%">British journal of urology</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">90-93</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Drinking</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Monitoring, Ambulatory/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Osmolar Concentration</style></keyword><keyword><style face="normal" font="default" size="100%">*Premenopause</style></keyword><keyword><style face="normal" font="default" size="100%">*Reagent Strips</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">Specific Gravity</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/diagnosis/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Urination</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1995</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0007-1331 (Print)&#xD;0007-1331</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To assess whether the use of simple hydration monitoring can encourage adequate hydration and reduce urinary osmolality and the incidence of urinary tract infections (UTIs) in a population of susceptible pre-menopausal women with recurrent idiopathic urinary infections. SUBJECTS AND METHODS: The study included 28 pre-menopausal women who had at least two idiopathic UTIs in the previous 6 months. Urinary osmolality was assessed by the patients at each void by a simple hand-held probe, and the readings over 4 months compared. Monthly urine culture was compared between successive 4-month periods in which the probe was or was not used. RESULTS: The study was completed by 17 women. There was a significant shift towards urine of lower osmolality over the 4-month period using the probe (Pearson&apos;s chi 2 &lt; 0.001). Significantly fewer urinary tract infections developed during the 4 months using the probe (McNemar&apos;s chi 2 = 0.046). CONCLUSIONS: The use of the osmolality probe encouraged the subject to maintain adequate hydration. The resulting augmentation of the natural urethral &apos;washout&apos; mechanism led to lower osmolality urine and a reduction in the incidence of UTIs.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Justin</style></label><notes><style face="normal" font="default" size="100%">Eckford, S D&#xD;Keane, D P&#xD;Lamond, E&#xD;Jackson, S R&#xD;Abrams, P&#xD;Clinical Trial&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;England&#xD;Br J Urol. 1995 Jul;76(1):90-3.</style></notes><urls></urls></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1911</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">1911</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Flower, A.</style></author><author><style face="normal" font="default" size="100%">Harman, K.</style></author><author><style face="normal" font="default" size="100%">Lewith, G.</style></author><author><style face="normal" font="default" size="100%">Moore, M.</style></author><author><style face="normal" font="default" size="100%">Bishop, F. L.</style></author><author><style face="normal" font="default" size="100%">Stuart, B.</style></author><author><style face="normal" font="default" size="100%">Lampert, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Health Research, Complementary and Integrated Medicine Research, University of Southampton, Aldermoor Close, Southampton, SO16 5ST, UK. Andrew.Flower@soton.ac.uk.&#xD;Primary Care &amp; Population Science, University of Southampton, Southampton, UK.&#xD;Health Research, Complementary and Integrated Medicine Research, University of Southampton, Southhampton, UK.&#xD;Psychology, University of Southampton, Faculty of Social, Human and Mathematical Sciences, Southampton, UK.&#xD;Birmingham Centre for Chinese Medicine, Birmingham, B14 6DT, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Standardised Chinese herbal treatment delivered by GPs compared with individualised treatment administered by practitioners of Chinese herbal medicine for women with recurrent urinary tract infections (RUTI): study protocol for a randomised controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">Trials</style></secondary-title><short-title><style face="normal" font="default" size="100%">Standardised Chinese herbal treatment delivered by GPs compared with individualised treatment administered by practitioners of Chinese herbal medicine for women with recurrent urinary tract infections (RUTI): study protocol for a randomised controlled trial</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Trials</style></full-title><abbr-1><style face="normal" font="default" size="100%">Trials</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">358</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Protocols</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drugs, Chinese Herbal/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">England</style></keyword><keyword><style face="normal" font="default" size="100%">Feasibility Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*General Practitioners</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Medication Adherence</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Satisfaction</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">Research Design</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/diagnosis/*drug therapy/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Chinese herbal medicine</style></keyword><keyword><style face="normal" font="default" size="100%">*Primary care</style></keyword><keyword><style face="normal" font="default" size="100%">*Urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">*feasibility</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 27</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1745-6215</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND: In the UK, urinary tract infections (UTIs) are the most common bacterial infection presented by women in primary care. Recurrent urinary tract infections (RUTIs) are defined as three episodes of UTI in the last 12 months, or two episodes in the last 6 months. Between 20 and 30 % of women who have had one episode of UTI will have an RUTI, and approximately 25 % of these will develop subsequent recurrent episodes. RUTIs can have a significant negative effect on the quality of life, and have a high impact on health care costs as a result of outpatient visits, diagnostic tests and prescriptions. Chinese herbal medicine (CHM) has a recorded history of treatments for the symptoms of UTIs for more than 2000 years. More recent clinical research in China has provided some preliminary evidence that CHM can alleviate the symptoms of UTIs and reduce the rate of recurrence, but more rigorous investigation is required. METHODS/DESIGN: The RUTI trial is a double-blind, randomised, placebo-controlled, feasibility trial. A total of 80 women will be randomised to &apos;individualised&apos; herbs prescribed by a Chinese herbal practitioner or to &apos;standardised&apos; herbs provided by primary care clinicians. Both arms will have herbs for prevention of UTIs and treatment of acute episodes. Treatment duration is for 16 weeks. The primary outcomes are the number of episodes of recurrent UTIs during the trial period and in the 6 months of follow-up, and the number of days of symptoms rated moderately bad or worse based on patient diaries. Secondary outcomes will assess participant expectations and beliefs, adherence to the treatment, adverse events and health economics and provide quantitative and qualitative assessments of the impact of recurrent infections on the lives of women. DISCUSSION: The RUTI trial is the first instance of CHM delivered as a clinical trial of an investigatory medicinal product in the UK. This study provides important information regarding the feasibility and acceptability of researching and using CHM in Primary care. Once completed, it will provide provisional estimates of the variance of change in continuous outcomes to inform a power calculation for a larger, more definitive trial. TRIAL REGISTRATION: EudraCT, 2013-004657-24 . Registered on 5 September 2014.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Anna</style></label><notes><style face="normal" font="default" size="100%">1745-6215&#xD;Flower, Andrew&#xD;Harman, Kim&#xD;Lewith, George&#xD;Moore, Michael&#xD;Bishop, Felicity L&#xD;Stuart, Beth&#xD;Lampert, Nicholas&#xD;Comparative Study&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s13063-016-1471-5.</style></electronic-resource-num></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2919</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">2919</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Flower, A.</style></author><author><style face="normal" font="default" size="100%">Harman, K.</style></author><author><style face="normal" font="default" size="100%">Lewith, G.</style></author><author><style face="normal" font="default" size="100%">Moore, M.</style></author><author><style face="normal" font="default" size="100%">Bishop, F. L.</style></author><author><style face="normal" font="default" size="100%">Stuart, B.</style></author><author><style face="normal" font="default" size="100%">Lampert, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Health Research, Complementary and Integrated Medicine Research, University of Southampton, Aldermoor Close, Southampton, SO16 5ST, UK. Andrew.Flower@soton.ac.uk.&#xD;Primary Care &amp; Population Science, University of Southampton, Southampton, UK.&#xD;Health Research, Complementary and Integrated Medicine Research, University of Southampton, Southhampton, UK.&#xD;Psychology, University of Southampton, Faculty of Social, Human and Mathematical Sciences, Southampton, UK.&#xD;Birmingham Centre for Chinese Medicine, Birmingham, B14 6DT, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Standardised Chinese herbal treatment delivered by GPs compared with individualised treatment administered by practitioners of Chinese herbal medicine for women with recurrent urinary tract infections (RUTI): study protocol for a randomised controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">Trials</style></secondary-title><short-title><style face="normal" font="default" size="100%">Standardised Chinese herbal treatment delivered by GPs compared with individualised treatment administered by practitioners of Chinese herbal medicine for women with recurrent urinary tract infections (RUTI): study protocol for a randomised controlled trial</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Trials</style></full-title><abbr-1><style face="normal" font="default" size="100%">Trials</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">358</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Protocols</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drugs, Chinese Herbal/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">England</style></keyword><keyword><style face="normal" font="default" size="100%">Feasibility Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*General Practitioners</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Medication Adherence</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Satisfaction</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">Research Design</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/diagnosis/*drug therapy/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Chinese herbal medicine</style></keyword><keyword><style face="normal" font="default" size="100%">*Primary care</style></keyword><keyword><style face="normal" font="default" size="100%">*Urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">*feasibility</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 27</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1745-6215</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND: In the UK, urinary tract infections (UTIs) are the most common bacterial infection presented by women in primary care. Recurrent urinary tract infections (RUTIs) are defined as three episodes of UTI in the last 12 months, or two episodes in the last 6 months. Between 20 and 30 % of women who have had one episode of UTI will have an RUTI, and approximately 25 % of these will develop subsequent recurrent episodes. RUTIs can have a significant negative effect on the quality of life, and have a high impact on health care costs as a result of outpatient visits, diagnostic tests and prescriptions. Chinese herbal medicine (CHM) has a recorded history of treatments for the symptoms of UTIs for more than 2000 years. More recent clinical research in China has provided some preliminary evidence that CHM can alleviate the symptoms of UTIs and reduce the rate of recurrence, but more rigorous investigation is required. METHODS/DESIGN: The RUTI trial is a double-blind, randomised, placebo-controlled, feasibility trial. A total of 80 women will be randomised to &apos;individualised&apos; herbs prescribed by a Chinese herbal practitioner or to &apos;standardised&apos; herbs provided by primary care clinicians. Both arms will have herbs for prevention of UTIs and treatment of acute episodes. Treatment duration is for 16 weeks. The primary outcomes are the number of episodes of recurrent UTIs during the trial period and in the 6 months of follow-up, and the number of days of symptoms rated moderately bad or worse based on patient diaries. Secondary outcomes will assess participant expectations and beliefs, adherence to the treatment, adverse events and health economics and provide quantitative and qualitative assessments of the impact of recurrent infections on the lives of women. DISCUSSION: The RUTI trial is the first instance of CHM delivered as a clinical trial of an investigatory medicinal product in the UK. This study provides important information regarding the feasibility and acceptability of researching and using CHM in Primary care. Once completed, it will provide provisional estimates of the variance of change in continuous outcomes to inform a power calculation for a larger, more definitive trial. TRIAL REGISTRATION: EudraCT, 2013-004657-24 . Registered on 5 September 2014.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Justin</style></label><notes><style face="normal" font="default" size="100%">1745-6215&#xD;Flower, Andrew&#xD;Harman, Kim&#xD;Lewith, George&#xD;Moore, Michael&#xD;Bishop, Felicity L&#xD;Stuart, Beth&#xD;Lampert, Nicholas&#xD;Comparative Study&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s13063-016-1471-5.</style></electronic-resource-num></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1943</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">1943</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Handeland, M.</style></author><author><style face="normal" font="default" size="100%">Grude, N.</style></author><author><style face="normal" font="default" size="100%">Torp, T.</style></author><author><style face="normal" font="default" size="100%">Slimestad, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Health Studies, University of Stavanger, Stavanger, Norway N-4036.&#xD;Department of Microbiology, Vestfold Hospital Trust, Tonsberg, Norway N-3103.&#xD;Norwegian Institute for Agricultural and Environmental Research, Plant Health and Plant Protection Division, Hogskoleveien 7, As, Norway N-1432.&#xD;Norwegian Institute for Agricultural and Environmental Research-Bioforsk Vest Saerheim, Postvegen 213, Klepp station, Klepp, Norway N-4353. Electronic address: Rune.Slimestad@bioforsk.no.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Black chokeberry juice (Aronia melanocarpa) reduces incidences of urinary tract infection among nursing home residents in the long term--a pilot study</style></title><secondary-title><style face="normal" font="default" size="100%">Nutr Res</style></secondary-title><short-title><style face="normal" font="default" size="100%">Black chokeberry juice (Aronia melanocarpa) reduces incidences of urinary tract infection among nursing home residents in the long term--a pilot study</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nutr Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Nutrition research (New York, N.Y.)</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">518-525</style></pages><volume><style face="normal" font="default" size="100%">34</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Anthocyanins/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Beverages/*analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Biflavonoids/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Catechin/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Chlorogenic Acid/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Over Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Fruit/*chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Photinia/*chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Pilot Projects</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidins/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Black chokeberry</style></keyword><keyword><style face="normal" font="default" size="100%">Elderly people</style></keyword><keyword><style face="normal" font="default" size="100%">Phenolics</style></keyword><keyword><style face="normal" font="default" size="100%">Uti</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0271-5317</style></isbn><abstract><style face="normal" font="default" size="100%">Urinary tract infection (UTI) is a major problem in nursing homes, and the mainstay of treatment is antibiotics. The increasing prevalence of uropathogens resistant to antimicrobial agents has stimulated interest in specific nutrients, for example, cranberries, to prevent recurring UTI. Black chokeberry (Aronia melanocarpa [Michx] Elliott) is a rich source of phenolics, and thus, dietary intake of black chokeberry juice may reduce the incidences of UTI requiring medical treatment. In this pilot study, we examined the frequency of medically treated UTI among residents in 6 nursing homes who were offered black chokeberry juice or a placebo during a 6-month crossover intervention. The residents were offered a placebo drink for a 3-month period followed by chokeberry juice for the next 3 months (group A) or vice versa (group B). The juice was characterized by a high content of total phenolics (715 mg gallic acid equivalent, 100 mL(-1)), including B-type procyanidins, anthocyanins, and chlorogenic acids. Daily intake of chokeberry juice was 156 mL per resident in group A (n = 110) and 89 mL per resident in group B (n = 126). Urinary tract infection comprised 55% of all medically treated infections during the study period. The results revealed no immediate reduction in the frequency of UTI or the total use of antibiotics; however, during the subsequent 3-month period of juice administration, a reduction in antibiotics toward UTI was observed in both groups. The incidence of UTI was reduced by 55% in group A and 38% in group B. No changes in other infections or in use of prophylactics were observed.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Anna</style></label><notes><style face="normal" font="default" size="100%">1879-0739&#xD;Handeland, Maria&#xD;Grude, Nils&#xD;Torp, Torfinn&#xD;Slimestad, Rune&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.nutres.2014.05.005. Epub 2014 Jun 3.</style></electronic-resource-num></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2923</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">2923</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Handeland, M.</style></author><author><style face="normal" font="default" size="100%">Grude, N.</style></author><author><style face="normal" font="default" size="100%">Torp, T.</style></author><author><style face="normal" font="default" size="100%">Slimestad, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Health Studies, University of Stavanger, Stavanger, Norway N-4036.&#xD;Department of Microbiology, Vestfold Hospital Trust, Tonsberg, Norway N-3103.&#xD;Norwegian Institute for Agricultural and Environmental Research, Plant Health and Plant Protection Division, Hogskoleveien 7, As, Norway N-1432.&#xD;Norwegian Institute for Agricultural and Environmental Research-Bioforsk Vest Saerheim, Postvegen 213, Klepp station, Klepp, Norway N-4353. Electronic address: Rune.Slimestad@bioforsk.no.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Black chokeberry juice (Aronia melanocarpa) reduces incidences of urinary tract infection among nursing home residents in the long term--a pilot study</style></title><secondary-title><style face="normal" font="default" size="100%">Nutr Res</style></secondary-title><short-title><style face="normal" font="default" size="100%">Black chokeberry juice (Aronia melanocarpa) reduces incidences of urinary tract infection among nursing home residents in the long term--a pilot study</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nutr Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Nutrition research (New York, N.Y.)</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">518-525</style></pages><volume><style face="normal" font="default" size="100%">34</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Anthocyanins/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Beverages/*analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Biflavonoids/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Catechin/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Chlorogenic Acid/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Over Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Fruit/*chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Photinia/*chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Pilot Projects</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidins/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Black chokeberry</style></keyword><keyword><style face="normal" font="default" size="100%">Elderly people</style></keyword><keyword><style face="normal" font="default" size="100%">Phenolics</style></keyword><keyword><style face="normal" font="default" size="100%">Uti</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0271-5317</style></isbn><abstract><style face="normal" font="default" size="100%">Urinary tract infection (UTI) is a major problem in nursing homes, and the mainstay of treatment is antibiotics. The increasing prevalence of uropathogens resistant to antimicrobial agents has stimulated interest in specific nutrients, for example, cranberries, to prevent recurring UTI. Black chokeberry (Aronia melanocarpa [Michx] Elliott) is a rich source of phenolics, and thus, dietary intake of black chokeberry juice may reduce the incidences of UTI requiring medical treatment. In this pilot study, we examined the frequency of medically treated UTI among residents in 6 nursing homes who were offered black chokeberry juice or a placebo during a 6-month crossover intervention. The residents were offered a placebo drink for a 3-month period followed by chokeberry juice for the next 3 months (group A) or vice versa (group B). The juice was characterized by a high content of total phenolics (715 mg gallic acid equivalent, 100 mL(-1)), including B-type procyanidins, anthocyanins, and chlorogenic acids. Daily intake of chokeberry juice was 156 mL per resident in group A (n = 110) and 89 mL per resident in group B (n = 126). Urinary tract infection comprised 55% of all medically treated infections during the study period. The results revealed no immediate reduction in the frequency of UTI or the total use of antibiotics; however, during the subsequent 3-month period of juice administration, a reduction in antibiotics toward UTI was observed in both groups. The incidence of UTI was reduced by 55% in group A and 38% in group B. No changes in other infections or in use of prophylactics were observed.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Justin</style></label><notes><style face="normal" font="default" size="100%">1879-0739&#xD;Handeland, Maria&#xD;Grude, Nils&#xD;Torp, Torfinn&#xD;Slimestad, Rune&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.nutres.2014.05.005. Epub 2014 Jun 3.</style></electronic-resource-num></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1962</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">1962</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoivik, H. O.</style></author><author><style face="normal" font="default" size="100%">Gundersen, R.</style></author><author><style face="normal" font="default" size="100%">Osmundsen, K.</style></author><author><style face="normal" font="default" size="100%">Halvorsen, P.</style></author><author><style face="normal" font="default" size="100%">Hjortdahl, P.</style></author><author><style face="normal" font="default" size="100%">Stokke, J. G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">[Prevention of recurrent cystitis in fertile women. A double-blind comparison of Hiprex and placebo in general practice]</style></title><secondary-title><style face="normal" font="default" size="100%">Tidsskr Nor Laegeforen</style></secondary-title><short-title><style face="normal" font="default" size="100%">[Prevention of recurrent cystitis in fertile women. A double-blind comparison of Hiprex and placebo in general practice]</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Tidsskr Nor Laegeforen</style></full-title><abbr-1><style face="normal" font="default" size="100%">Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">1150-1152</style></pages><volume><style face="normal" font="default" size="100%">104</style></volume><number><style face="normal" font="default" size="100%">16</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Cystitis/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Hippurates/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Methenamine/*analogs &amp; derivatives/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1984</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 10</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0029-2001 (Print)&#xD;0029-2001</style></isbn><label><style face="normal" font="default" size="100%">Yes - Anna</style></label><notes><style face="normal" font="default" size="100%">Hoivik, H O&#xD;Gundersen, R&#xD;Osmundsen, K&#xD;Halvorsen, P&#xD;Hjortdahl, P&#xD;Stokke, J G&#xD;Clinical Trial&#xD;Comparative Study&#xD;English Abstract&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Norway&#xD;Tidsskr Nor Laegeforen. 1984 Jun 10;104(16):1150-2.</style></notes><urls></urls></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2925</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">2925</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoivik, H. O.</style></author><author><style face="normal" font="default" size="100%">Gundersen, R.</style></author><author><style face="normal" font="default" size="100%">Osmundsen, K.</style></author><author><style face="normal" font="default" size="100%">Halvorsen, P.</style></author><author><style face="normal" font="default" size="100%">Hjortdahl, P.</style></author><author><style face="normal" font="default" size="100%">Stokke, J. G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">[Prevention of recurrent cystitis in fertile women. A double-blind comparison of Hiprex and placebo in general practice]</style></title><secondary-title><style face="normal" font="default" size="100%">Tidsskr Nor Laegeforen</style></secondary-title><short-title><style face="normal" font="default" size="100%">[Prevention of recurrent cystitis in fertile women. A double-blind comparison of Hiprex and placebo in general practice]</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Tidsskr Nor Laegeforen</style></full-title><abbr-1><style face="normal" font="default" size="100%">Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">1150-1152</style></pages><volume><style face="normal" font="default" size="100%">104</style></volume><number><style face="normal" font="default" size="100%">16</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Cystitis/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Hippurates/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Methenamine/*analogs &amp; derivatives/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1984</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 10</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0029-2001 (Print)&#xD;0029-2001</style></isbn><label><style face="normal" font="default" size="100%">Yes - Justin</style></label><notes><style face="normal" font="default" size="100%">Hoivik, H O&#xD;Gundersen, R&#xD;Osmundsen, K&#xD;Halvorsen, P&#xD;Hjortdahl, P&#xD;Stokke, J G&#xD;Clinical Trial&#xD;Comparative Study&#xD;English Abstract&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Norway&#xD;Tidsskr Nor Laegeforen. 1984 Jun 10;104(16):1150-2.</style></notes><urls></urls></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1966</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">1966</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hooton, T. M.</style></author><author><style face="normal" font="default" size="100%">Vecchio, M.</style></author><author><style face="normal" font="default" size="100%">Iroz, A.</style></author><author><style face="normal" font="default" size="100%">Tack, I.</style></author><author><style face="normal" font="default" size="100%">Dornic, Q.</style></author><author><style face="normal" font="default" size="100%">Seksek, I.</style></author><author><style face="normal" font="default" size="100%">Lotan, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, School of Medicine, University of Miami, Miami, Florida.&#xD;Danone Nutricia Research, Palaiseau, France.&#xD;Service des Explorations Fonctionnelles Physiologiques, CHU de Toulouse, Universite Paul Sabatier, Toulouse, France.&#xD;Department of Urology, University of Texas Southwestern Medical Center, Dallas.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections: A Randomized Clinical Trial</style></title><secondary-title><style face="normal" font="default" size="100%">JAMA Intern Med</style></secondary-title><short-title><style face="normal" font="default" size="100%">Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections: A Randomized Clinical Trial</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">JAMA Intern Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">JAMA internal medicine</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">1509-1515</style></pages><volume><style face="normal" font="default" size="100%">178</style></volume><number><style face="normal" font="default" size="100%">11</style></number><dates><year><style face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2168-6106</style></isbn><abstract><style face="normal" font="default" size="100%">Importance: Increased hydration is often recommended as a preventive measure for women with recurrent cystitis, but supportive data are sparse. Objective: To assess the efficacy of increased daily water intake on the frequency of recurrent cystitis in premenopausal women. Design, Setting, and Participants: Randomized, open-label, controlled, 12-month trial at a clinical research center (years 2013-2016). Among 163 healthy women with recurrent cystitis (&gt;/=3 episodes in past year) drinking less than 1.5 L of fluid daily assessed for eligibility, 23 were excluded and 140 assigned to water or control group. Assessments of daily fluid intake, urinary hydration, and cystitis symptoms were performed at baseline, 6- and 12-month visits, and monthly telephone calls. Interventions: Participants were randomly assigned to drink, in addition to their usual fluid intake, 1.5 L of water daily (water group) or no additional fluids (control group) for 12 months. Main Outcomes and Measures: Primary outcome measure was frequency of recurrent cystitis over 12 months. Secondary outcomes were number of antimicrobial regimens used, mean time interval between cystitis episodes, and 24-hour urinary hydration measurements. Results: The mean (SD) age of the 140 participants was 35.7 (8.4) years, and the mean (SD) number of cystitis episodes in the previous year was 3.3 (0.6). During the 12-month study period, the mean (SD) number of cystitis episodes was 1.7 (95% CI, 1.5-1.8) in the water group compared with 3.2 (95% CI, 3.0-3.4) in the control group, with a difference in means of 1.5 (95% CI, 1.2-1.8; P &lt; .001). Overall, there were 327 cystitis episodes, 111 in the water group and 216 in the control group. The mean number of antimicrobial regimens used to treat cystitis episodes was 1.9 (95% CI, 1.7-2.2) and 3.6 (95% CI, 3.3-4.0), respectively, with a difference in means of 1.7 (95% CI, 1.3-2.1; P &lt; .001). The mean time interval between cystitis episodes was 142.8 (95% CI, 127.4-160.1) and 84.4 (95% CI, 75.4-94.5) days, respectively, with a difference in means of 58.4 (95% CI, 39.4-77.4; P &lt; .001). Between baseline and 12 months, participants in the water group, compared with those in the control group, had increased mean (SD) urine volume (1.4 [0.04] vs 0.1 [0.04] L; P &lt; .001) and voids (2.4 [0.2] vs -0.1 [0.2]; P &lt; .001) and decreased urine osmolality (-402.8 [19.6] vs -24.0 [19.5] mOsm/kg; P &lt; .001). Conclusions and Relevance: Increased water intake is an effective antimicrobial-sparing strategy to prevent recurrent cystitis in premenopausal women at high risk for recurrence who drink low volumes of fluid daily. Trial Registration: ClinicalTrials.gov identifier: NCT02444975.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Anna</style></label><notes><style face="normal" font="default" size="100%">2168-6114&#xD;Hooton, Thomas M&#xD;Vecchio, Mariacristina&#xD;Iroz, Alison&#xD;Tack, Ivan&#xD;Dornic, Quentin&#xD;Seksek, Isabelle&#xD;Lotan, Yair&#xD;Journal Article&#xD;United States</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/jamainternmed.2018.4204.</style></electronic-resource-num></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2926</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">2926</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hooton, T. M.</style></author><author><style face="normal" font="default" size="100%">Vecchio, M.</style></author><author><style face="normal" font="default" size="100%">Iroz, A.</style></author><author><style face="normal" font="default" size="100%">Tack, I.</style></author><author><style face="normal" font="default" size="100%">Dornic, Q.</style></author><author><style face="normal" font="default" size="100%">Seksek, I.</style></author><author><style face="normal" font="default" size="100%">Lotan, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, School of Medicine, University of Miami, Miami, Florida.&#xD;Danone Nutricia Research, Palaiseau, France.&#xD;Service des Explorations Fonctionnelles Physiologiques, CHU de Toulouse, Universite Paul Sabatier, Toulouse, France.&#xD;Department of Urology, University of Texas Southwestern Medical Center, Dallas.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections: A Randomized Clinical Trial</style></title><secondary-title><style face="normal" font="default" size="100%">JAMA Intern Med</style></secondary-title><short-title><style face="normal" font="default" size="100%">Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections: A Randomized Clinical Trial</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">JAMA Intern Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">JAMA internal medicine</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">1509-1515</style></pages><volume><style face="normal" font="default" size="100%">178</style></volume><number><style face="normal" font="default" size="100%">11</style></number><dates><year><style face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2168-6106</style></isbn><abstract><style face="normal" font="default" size="100%">Importance: Increased hydration is often recommended as a preventive measure for women with recurrent cystitis, but supportive data are sparse. Objective: To assess the efficacy of increased daily water intake on the frequency of recurrent cystitis in premenopausal women. Design, Setting, and Participants: Randomized, open-label, controlled, 12-month trial at a clinical research center (years 2013-2016). Among 163 healthy women with recurrent cystitis (&gt;/=3 episodes in past year) drinking less than 1.5 L of fluid daily assessed for eligibility, 23 were excluded and 140 assigned to water or control group. Assessments of daily fluid intake, urinary hydration, and cystitis symptoms were performed at baseline, 6- and 12-month visits, and monthly telephone calls. Interventions: Participants were randomly assigned to drink, in addition to their usual fluid intake, 1.5 L of water daily (water group) or no additional fluids (control group) for 12 months. Main Outcomes and Measures: Primary outcome measure was frequency of recurrent cystitis over 12 months. Secondary outcomes were number of antimicrobial regimens used, mean time interval between cystitis episodes, and 24-hour urinary hydration measurements. Results: The mean (SD) age of the 140 participants was 35.7 (8.4) years, and the mean (SD) number of cystitis episodes in the previous year was 3.3 (0.6). During the 12-month study period, the mean (SD) number of cystitis episodes was 1.7 (95% CI, 1.5-1.8) in the water group compared with 3.2 (95% CI, 3.0-3.4) in the control group, with a difference in means of 1.5 (95% CI, 1.2-1.8; P &lt; .001). Overall, there were 327 cystitis episodes, 111 in the water group and 216 in the control group. The mean number of antimicrobial regimens used to treat cystitis episodes was 1.9 (95% CI, 1.7-2.2) and 3.6 (95% CI, 3.3-4.0), respectively, with a difference in means of 1.7 (95% CI, 1.3-2.1; P &lt; .001). The mean time interval between cystitis episodes was 142.8 (95% CI, 127.4-160.1) and 84.4 (95% CI, 75.4-94.5) days, respectively, with a difference in means of 58.4 (95% CI, 39.4-77.4; P &lt; .001). Between baseline and 12 months, participants in the water group, compared with those in the control group, had increased mean (SD) urine volume (1.4 [0.04] vs 0.1 [0.04] L; P &lt; .001) and voids (2.4 [0.2] vs -0.1 [0.2]; P &lt; .001) and decreased urine osmolality (-402.8 [19.6] vs -24.0 [19.5] mOsm/kg; P &lt; .001). Conclusions and Relevance: Increased water intake is an effective antimicrobial-sparing strategy to prevent recurrent cystitis in premenopausal women at high risk for recurrence who drink low volumes of fluid daily. Trial Registration: ClinicalTrials.gov identifier: NCT02444975.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Justin</style></label><notes><style face="normal" font="default" size="100%">2168-6114&#xD;Hooton, Thomas M&#xD;Vecchio, Mariacristina&#xD;Iroz, Alison&#xD;Tack, Ivan&#xD;Dornic, Quentin&#xD;Seksek, Isabelle&#xD;Lotan, Yair&#xD;Journal Article&#xD;United States</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/jamainternmed.2018.4204.</style></electronic-resource-num></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1977</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">1977</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Iroz, A.</style></author><author><style face="normal" font="default" size="100%">Dornic, Q.</style></author><author><style face="normal" font="default" size="100%">Seksek, I.</style></author><author><style face="normal" font="default" size="100%">Vecchio, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Increased water intake for the prevention of recurrent urinary tract infectionsdoes not affect quality of life in women</style></title><secondary-title><style face="normal" font="default" size="100%">Nephrology dialysis transplantation. Conference: 55th annual congress of the european renal association-european dialysis and transplant association, ERA-EDTA 2018. Denmark</style></secondary-title><short-title><style face="normal" font="default" size="100%">Increased water intake for the prevention of recurrent urinary tract infectionsdoes not affect quality of life in women</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nephrology dialysis transplantation. Conference: 55th annual congress of the european renal association-european dialysis and transplant association, ERA-EDTA 2018. Denmark</style></full-title></periodical><pages><style face="normal" font="default" size="100%">i25</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">Supplement 1</style></number><keywords><keyword><style face="normal" font="default" size="100%">*fluid intake</style></keyword><keyword><style face="normal" font="default" size="100%">*quality of life</style></keyword><keyword><style face="normal" font="default" size="100%">*urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Follow up</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword><keyword><style face="normal" font="default" size="100%">Major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">Mental health</style></keyword><keyword><style face="normal" font="default" size="100%">Pollakisuria</style></keyword><keyword><style face="normal" font="default" size="100%">Post hoc analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Premenopause</style></keyword><keyword><style face="normal" font="default" size="100%">Primary health care</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized controlled trial</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Introduction and Aims:Water intake is recommended by clinicians as part of standard preventive measures for a range of urinary tract related disease, however, women are reluctant to increase fluid intake in part due to the associated increase in micturition perceived to negatively impact their quality of life (QoL). The study analyzes the effect of increased water intake on quality of life in women with recurrent symptomatic urinary tract infections (UTI). As a secondary objective we also explore the relationship of recurrent UTI on quality of life. Methods: 140 healthy premenopausal women drinking less than 1.5 liters (L) of total fluid daily and suffering from recurrent UTI were randomized to receive, in addition to their usual daily fluid intake, either 1.5 L water daily (WG) or no additional fluids (CG), for 12 months. Number of micturition&apos;s and the SF‐12v2 survey, to measure QoL, were performed at baseline, 6‐and 12‐month follow‐up. Results: During the 12 months, women in the WG effectively increased their total fluid intake from 1.12 L/day at baseline, to 2.77 L/day and the number of micturition&apos;s increased from 6.061.6 events at baseline in the WG to 8.261.7 at 12 months. Physical health component norm based scores reported at 12 months remained similar to those reported at baseline for both the WG (55.58 6 4.13 vs. 56.77 6 2.28) and CG (54.76 6 5.69 vs. 56.14 6 3.27). Similar results were reported for the mental health component norm based scores with baseline and 12 month scores remaining consistent throughout the study for both the WG (53.28 6 7.13 vs. 57.14 6 5.22) and CG (51.93 6 8.18 vs. 56.09 6 5.57). QoL scores remained similar to those reported at baseline for both groups. Scores were consistent between groups at baseline and at the 6 and 12 month survey for all QoL domains. The percentage of women who reported abelow normal QoL (post‐hoc analysis) was significantly greater in women experiencing high UTI occurrence in both the role physical (68.65 % vs. 83.56 for high and low UTI occur‐rence, respectively, p&lt;0.05) and social functional (73.13% vs 91.78% for high and low UTI occurrence, respectively, p&lt;0.05) Conclusions: While UTI symptoms maybe considered benign, recurrent UTI negatively impacts QoL in women. Primary health care providers should reassure women with recurrent UTI that their QoL will not be impacted by increasing water intake despite more frequent urination.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Anna</style></label><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01613376/full</style></url></related-urls></urls></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2929</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">2929</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Iroz, A.</style></author><author><style face="normal" font="default" size="100%">Dornic, Q.</style></author><author><style face="normal" font="default" size="100%">Seksek, I.</style></author><author><style face="normal" font="default" size="100%">Vecchio, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Increased water intake for the prevention of recurrent urinary tract infectionsdoes not affect quality of life in women</style></title><secondary-title><style face="normal" font="default" size="100%">Nephrology dialysis transplantation. Conference: 55th annual congress of the european renal association-european dialysis and transplant association, ERA-EDTA 2018. Denmark</style></secondary-title><short-title><style face="normal" font="default" size="100%">Increased water intake for the prevention of recurrent urinary tract infectionsdoes not affect quality of life in women</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nephrology dialysis transplantation. Conference: 55th annual congress of the european renal association-european dialysis and transplant association, ERA-EDTA 2018. Denmark</style></full-title></periodical><pages><style face="normal" font="default" size="100%">i25</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">Supplement 1</style></number><keywords><keyword><style face="normal" font="default" size="100%">*fluid intake</style></keyword><keyword><style face="normal" font="default" size="100%">*quality of life</style></keyword><keyword><style face="normal" font="default" size="100%">*urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Follow up</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword><keyword><style face="normal" font="default" size="100%">Major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">Mental health</style></keyword><keyword><style face="normal" font="default" size="100%">Pollakisuria</style></keyword><keyword><style face="normal" font="default" size="100%">Post hoc analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Premenopause</style></keyword><keyword><style face="normal" font="default" size="100%">Primary health care</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized controlled trial</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Introduction and Aims:Water intake is recommended by clinicians as part of standard preventive measures for a range of urinary tract related disease, however, women are reluctant to increase fluid intake in part due to the associated increase in micturition perceived to negatively impact their quality of life (QoL). The study analyzes the effect of increased water intake on quality of life in women with recurrent symptomatic urinary tract infections (UTI). As a secondary objective we also explore the relationship of recurrent UTI on quality of life. Methods: 140 healthy premenopausal women drinking less than 1.5 liters (L) of total fluid daily and suffering from recurrent UTI were randomized to receive, in addition to their usual daily fluid intake, either 1.5 L water daily (WG) or no additional fluids (CG), for 12 months. Number of micturition&apos;s and the SF‐12v2 survey, to measure QoL, were performed at baseline, 6‐and 12‐month follow‐up. Results: During the 12 months, women in the WG effectively increased their total fluid intake from 1.12 L/day at baseline, to 2.77 L/day and the number of micturition&apos;s increased from 6.061.6 events at baseline in the WG to 8.261.7 at 12 months. Physical health component norm based scores reported at 12 months remained similar to those reported at baseline for both the WG (55.58 6 4.13 vs. 56.77 6 2.28) and CG (54.76 6 5.69 vs. 56.14 6 3.27). Similar results were reported for the mental health component norm based scores with baseline and 12 month scores remaining consistent throughout the study for both the WG (53.28 6 7.13 vs. 57.14 6 5.22) and CG (51.93 6 8.18 vs. 56.09 6 5.57). QoL scores remained similar to those reported at baseline for both groups. Scores were consistent between groups at baseline and at the 6 and 12 month survey for all QoL domains. The percentage of women who reported abelow normal QoL (post‐hoc analysis) was significantly greater in women experiencing high UTI occurrence in both the role physical (68.65 % vs. 83.56 for high and low UTI occur‐rence, respectively, p&lt;0.05) and social functional (73.13% vs 91.78% for high and low UTI occurrence, respectively, p&lt;0.05) Conclusions: While UTI symptoms maybe considered benign, recurrent UTI negatively impacts QoL in women. Primary health care providers should reassure women with recurrent UTI that their QoL will not be impacted by increasing water intake despite more frequent urination.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Justin</style></label><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01613376/full</style></url></related-urls></urls></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2028</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">2028</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kranjcec, B.</style></author><author><style face="normal" font="default" size="100%">Papes, D.</style></author><author><style face="normal" font="default" size="100%">Altarac, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medical Biochemistry, Zabok General Hospital, Zabok, Croatia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial</style></title><secondary-title><style face="normal" font="default" size="100%">World J Urol</style></secondary-title><short-title><style face="normal" font="default" size="100%">D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">World J Urol</style></full-title><abbr-1><style face="normal" font="default" size="100%">World journal of urology</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">79-84</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Infective Agents, Urinary/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Mannose/*administration &amp; dosage/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Nitrofurantoin/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Powders</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Secondary Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/drug therapy/*epidemiology/*prevention &amp; control</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0724-4983</style></isbn><abstract><style face="normal" font="default" size="100%">PURPOSE: To test whether D-mannose powder is effective for recurrent urinary tract infection (UTI) prevention. MATERIALS AND METHODS: After initial antibiotic treatment of acute cystitis, 308 women with history of recurrent UTI and no other significant comorbidities were randomly allocated to three groups. The first group (n = 103) received prophylaxis with 2 g of D-mannose powder in 200 ml of water daily for 6 months, the second (n = 103) received 50 mg Nitrofurantoin daily, and the third (n = 102) did not receive prophylaxis. RESULTS: Overall 98 patients (31.8%) had recurrent UTI: 15 (14.6) in the D-mannose group, 21 (20.4) in Nitrofurantoin group, and 62 (60.8) in no prophylaxis group, with the rate significantly higher in no prophylaxis group compared to active groups (P &lt; 0.001). Patients in D-mannose group and Nitrofurantoin group had a significantly lower risk of recurrent UTI episode during prophylactic therapy compared to patients in no prophylaxis group (RR 0.239 and 0.335, P &lt; 0.0001). In active groups, 17.9% of patients reported side effects but they were mild and did not require stopping the prophylaxis. Patients in D-mannose group had a significantly lower risk of side effects compared to patients in Nitrofurantoin group (RR 0.276, P &lt; 0.0001), but the clinical importance of this finding is low because Nitrofurantoin was well tolerated. CONCLUSIONS: In our study, D-mannose powder had significantly reduced the risk of recurrent UTI which was no different than in Nitrofurantoin group. More studies will be needed to validate the results of this study, but initial findings show that D-mannose may be useful for UTI prevention.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Anna</style></label><notes><style face="normal" font="default" size="100%">1433-8726&#xD;Kranjcec, Bojana&#xD;Papes, Dino&#xD;Altarac, Silvio&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Germany</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00345-013-1091-6. Epub 2013 Apr 30.</style></electronic-resource-num></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2934</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">2934</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kranjcec, B.</style></author><author><style face="normal" font="default" size="100%">Papes, D.</style></author><author><style face="normal" font="default" size="100%">Altarac, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medical Biochemistry, Zabok General Hospital, Zabok, Croatia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial</style></title><secondary-title><style face="normal" font="default" size="100%">World J Urol</style></secondary-title><short-title><style face="normal" font="default" size="100%">D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">World J Urol</style></full-title><abbr-1><style face="normal" font="default" size="100%">World journal of urology</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">79-84</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Infective Agents, Urinary/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Mannose/*administration &amp; dosage/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Nitrofurantoin/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Powders</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Secondary Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/drug therapy/*epidemiology/*prevention &amp; control</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0724-4983</style></isbn><abstract><style face="normal" font="default" size="100%">PURPOSE: To test whether D-mannose powder is effective for recurrent urinary tract infection (UTI) prevention. MATERIALS AND METHODS: After initial antibiotic treatment of acute cystitis, 308 women with history of recurrent UTI and no other significant comorbidities were randomly allocated to three groups. The first group (n = 103) received prophylaxis with 2 g of D-mannose powder in 200 ml of water daily for 6 months, the second (n = 103) received 50 mg Nitrofurantoin daily, and the third (n = 102) did not receive prophylaxis. RESULTS: Overall 98 patients (31.8%) had recurrent UTI: 15 (14.6) in the D-mannose group, 21 (20.4) in Nitrofurantoin group, and 62 (60.8) in no prophylaxis group, with the rate significantly higher in no prophylaxis group compared to active groups (P &lt; 0.001). Patients in D-mannose group and Nitrofurantoin group had a significantly lower risk of recurrent UTI episode during prophylactic therapy compared to patients in no prophylaxis group (RR 0.239 and 0.335, P &lt; 0.0001). In active groups, 17.9% of patients reported side effects but they were mild and did not require stopping the prophylaxis. Patients in D-mannose group had a significantly lower risk of side effects compared to patients in Nitrofurantoin group (RR 0.276, P &lt; 0.0001), but the clinical importance of this finding is low because Nitrofurantoin was well tolerated. CONCLUSIONS: In our study, D-mannose powder had significantly reduced the risk of recurrent UTI which was no different than in Nitrofurantoin group. More studies will be needed to validate the results of this study, but initial findings show that D-mannose may be useful for UTI prevention.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Justin</style></label><notes><style face="normal" font="default" size="100%">1433-8726&#xD;Kranjcec, Bojana&#xD;Papes, Dino&#xD;Altarac, Silvio&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Germany</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00345-013-1091-6. Epub 2013 Apr 30.</style></electronic-resource-num></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2041</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">2041</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, B. B.</style></author><author><style face="normal" font="default" size="100%">Toh, S. L.</style></author><author><style face="normal" font="default" size="100%">Ryan, S.</style></author><author><style face="normal" font="default" size="100%">Simpson, J. M.</style></author><author><style face="normal" font="default" size="100%">Clezy, K.</style></author><author><style face="normal" font="default" size="100%">Bossa, L.</style></author><author><style face="normal" font="default" size="100%">Rice, S. A.</style></author><author><style face="normal" font="default" size="100%">Marial, O.</style></author><author><style face="normal" font="default" size="100%">Weber, G.</style></author><author><style face="normal" font="default" size="100%">Kaur, J.</style></author><author><style face="normal" font="default" size="100%">Boswell-Ruys, C.</style></author><author><style face="normal" font="default" size="100%">Goodall, S.</style></author><author><style face="normal" font="default" size="100%">Middleton, J.</style></author><author><style face="normal" font="default" size="100%">Tudehope, M.</style></author><author><style face="normal" font="default" size="100%">Kotsiou, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Neuroscience Research Australia [NeuRA] and the University of New South Wales, Sydney, Australia.&#xD;Department of Spinal and Rehabilitation Medicine, Prince of Wales Hospital, Sydney, Australia.&#xD;Department of Spinal and Rehabilitation Medicine, Prince of Wales Hospital, Sydney, Australia. SweeLing.Toh@health.nsw.gov.au.&#xD;School of Public Health, University of Sydney, Sydney, Australia. SweeLing.Toh@health.nsw.gov.au.&#xD;School of Public Health, University of Sydney, Sydney, Australia.&#xD;Department of Infectious Diseases, Prince of Wales Hospital, Sydney, Australia.&#xD;Centre for Marine Bio-Innovation, University of New South Wales, Sydney, Australia.&#xD;The Singapore Centre for Life Sciences Engineering and the School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.&#xD;Royal Rehabilitation Centre Sydney, Sydney, Australia.&#xD;Royal North Shore Hospital, Sydney, Australia.&#xD;Centre for Health Economics Research and Evaluation [CHERE], University of Technology Sydney, Sydney, Australia.&#xD;John Walsh Centre for Rehabilitation Research, Kolling Institute, Northern Sydney Local Health District, St Leonards, NSW, 2065, Australia.&#xD;Sydney Medical School Northern, University of Sydney, Sydney, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Probiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in persons with spinal cord injury [ProSCIUTTU]: a study protocol for a randomised controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Urol</style></secondary-title><short-title><style face="normal" font="default" size="100%">Probiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in persons with spinal cord injury [ProSCIUTTU]: a study protocol for a randomised controlled trial</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMC Urol</style></full-title><abbr-1><style face="normal" font="default" size="100%">BMC urology</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">18</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Bifidobacterium</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Kaplan-Meier Estimate</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacillus reuteri</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacillus rhamnosus</style></keyword><keyword><style face="normal" font="default" size="100%">New South Wales</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default" size="100%">Spinal Cord Injuries/*complications</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Bladder, Neurogenic/*complications</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/etiology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Antibiotic resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Biofilm</style></keyword><keyword><style face="normal" font="default" size="100%">Microbial community profiles</style></keyword><keyword><style face="normal" font="default" size="100%">Multi-resistant organisms</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary prophylaxis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 16</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1471-2490</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND: Urinary tract infections [UTIs] are very common in people with Spinal Cord Injury [SCI]. UTIs are increasingly difficult and expensive to treat as the organisms that cause them become more antibiotic resistant. Among the SCI population, there is a high rate of multi-resistant organism [MRO] colonisation. Non-antibiotic prevention strategies are needed to prevent UTI without increasing resistance. Probiotics have been reported to be beneficial in preventing UTIs in post-menopausal women in several in vivo and in vitro studies. The main aim of this study is to determine whether probiotic therapy with combinations of Lactobacillus reuteri RC-14 + Lactobacillus rhamnosus GR-1 [RC14-GR1] and/or Lactobacillus rhamnosus GG + Bifidobacterium BB-12 [LGG-BB12] are effective in preventing UTI in people with SCI compared to placebo. METHOD: This is a multi-site randomised double-blind double-dummy placebo-controlled factorial design study conducted in New South Wales, Australia. All participants have a neurogenic bladder as a result of spinal injury. Recruitment started in April 2011. Participants are randomised to one of four arms, designed for factorial analysis of LGG-BB12 and/or RC14-GR1 v Placebo. This involves 24 weeks of daily oral treatment with RC14-GR1 + LGG-BB12, RC14-GR1 + placebo, LGG-BB12 + placebo or two placebo capsules. Randomisation is stratified by bladder management type and inpatient status. Participants are assessed at baseline, three months and six months for Short Form Health Survey [SF-36], microbiological swabs of rectum, nose and groin; urine culture and urinary catheters for subjects with indwelling catheters. A bowel questionnaire is administered at baseline and three months to assess effect of probiotics on bowel function. The primary outcome is time from randomisation to occurrence of symptomatic UTI. The secondary outcomes are change of MRO status and bowel function, quality of life and cost-effectiveness of probiotics in persons with SCI. The primary outcome will be analysed using survival analysis of factorial groups, with Cox regression modelling to test the effect of each treatment while allowing for the other, assuming no interaction effect. Hazard ratios and Kaplan-Meier survival curves will be used to summarise results. DISCUSSION: If these probiotics are shown to be effective in preventing UTI and MRO colonisation, they would be a very attractive alternative for UTI prophylaxis and for combating the increasing rate of antibiotic resistance after SCI. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry [ ACTRN 12610000512022 ]. Date of registration: 21 June 2010.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Anna</style></label><notes><style face="normal" font="default" size="100%">1471-2490&#xD;Lee, Bonsan Bonne&#xD;Toh, Swee-Ling&#xD;Ryan, Suzanne&#xD;Simpson, Judy M&#xD;Clezy, Kate&#xD;Bossa, Laetitia&#xD;Rice, Scott A&#xD;Marial, Obaydullah&#xD;Weber, Gerard&#xD;Kaur, Jasbeer&#xD;Boswell-Ruys, Claire&#xD;Goodall, Stephen&#xD;Middleton, James&#xD;Tudehope, Mark&#xD;Kotsiou, George&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s12894-016-0136-8.</style></electronic-resource-num></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2935</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">2935</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, B. B.</style></author><author><style face="normal" font="default" size="100%">Toh, S. L.</style></author><author><style face="normal" font="default" size="100%">Ryan, S.</style></author><author><style face="normal" font="default" size="100%">Simpson, J. M.</style></author><author><style face="normal" font="default" size="100%">Clezy, K.</style></author><author><style face="normal" font="default" size="100%">Bossa, L.</style></author><author><style face="normal" font="default" size="100%">Rice, S. A.</style></author><author><style face="normal" font="default" size="100%">Marial, O.</style></author><author><style face="normal" font="default" size="100%">Weber, G.</style></author><author><style face="normal" font="default" size="100%">Kaur, J.</style></author><author><style face="normal" font="default" size="100%">Boswell-Ruys, C.</style></author><author><style face="normal" font="default" size="100%">Goodall, S.</style></author><author><style face="normal" font="default" size="100%">Middleton, J.</style></author><author><style face="normal" font="default" size="100%">Tudehope, M.</style></author><author><style face="normal" font="default" size="100%">Kotsiou, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Neuroscience Research Australia [NeuRA] and the University of New South Wales, Sydney, Australia.&#xD;Department of Spinal and Rehabilitation Medicine, Prince of Wales Hospital, Sydney, Australia.&#xD;Department of Spinal and Rehabilitation Medicine, Prince of Wales Hospital, Sydney, Australia. SweeLing.Toh@health.nsw.gov.au.&#xD;School of Public Health, University of Sydney, Sydney, Australia. SweeLing.Toh@health.nsw.gov.au.&#xD;School of Public Health, University of Sydney, Sydney, Australia.&#xD;Department of Infectious Diseases, Prince of Wales Hospital, Sydney, Australia.&#xD;Centre for Marine Bio-Innovation, University of New South Wales, Sydney, Australia.&#xD;The Singapore Centre for Life Sciences Engineering and the School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.&#xD;Royal Rehabilitation Centre Sydney, Sydney, Australia.&#xD;Royal North Shore Hospital, Sydney, Australia.&#xD;Centre for Health Economics Research and Evaluation [CHERE], University of Technology Sydney, Sydney, Australia.&#xD;John Walsh Centre for Rehabilitation Research, Kolling Institute, Northern Sydney Local Health District, St Leonards, NSW, 2065, Australia.&#xD;Sydney Medical School Northern, University of Sydney, Sydney, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Probiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in persons with spinal cord injury [ProSCIUTTU]: a study protocol for a randomised controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Urol</style></secondary-title><short-title><style face="normal" font="default" size="100%">Probiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in persons with spinal cord injury [ProSCIUTTU]: a study protocol for a randomised controlled trial</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMC Urol</style></full-title><abbr-1><style face="normal" font="default" size="100%">BMC urology</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">18</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Bifidobacterium</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Kaplan-Meier Estimate</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacillus reuteri</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacillus rhamnosus</style></keyword><keyword><style face="normal" font="default" size="100%">New South Wales</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default" size="100%">Spinal Cord Injuries/*complications</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Bladder, Neurogenic/*complications</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/etiology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Antibiotic resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Biofilm</style></keyword><keyword><style face="normal" font="default" size="100%">Microbial community profiles</style></keyword><keyword><style face="normal" font="default" size="100%">Multi-resistant organisms</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary prophylaxis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 16</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1471-2490</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND: Urinary tract infections [UTIs] are very common in people with Spinal Cord Injury [SCI]. UTIs are increasingly difficult and expensive to treat as the organisms that cause them become more antibiotic resistant. Among the SCI population, there is a high rate of multi-resistant organism [MRO] colonisation. Non-antibiotic prevention strategies are needed to prevent UTI without increasing resistance. Probiotics have been reported to be beneficial in preventing UTIs in post-menopausal women in several in vivo and in vitro studies. The main aim of this study is to determine whether probiotic therapy with combinations of Lactobacillus reuteri RC-14 + Lactobacillus rhamnosus GR-1 [RC14-GR1] and/or Lactobacillus rhamnosus GG + Bifidobacterium BB-12 [LGG-BB12] are effective in preventing UTI in people with SCI compared to placebo. METHOD: This is a multi-site randomised double-blind double-dummy placebo-controlled factorial design study conducted in New South Wales, Australia. All participants have a neurogenic bladder as a result of spinal injury. Recruitment started in April 2011. Participants are randomised to one of four arms, designed for factorial analysis of LGG-BB12 and/or RC14-GR1 v Placebo. This involves 24 weeks of daily oral treatment with RC14-GR1 + LGG-BB12, RC14-GR1 + placebo, LGG-BB12 + placebo or two placebo capsules. Randomisation is stratified by bladder management type and inpatient status. Participants are assessed at baseline, three months and six months for Short Form Health Survey [SF-36], microbiological swabs of rectum, nose and groin; urine culture and urinary catheters for subjects with indwelling catheters. A bowel questionnaire is administered at baseline and three months to assess effect of probiotics on bowel function. The primary outcome is time from randomisation to occurrence of symptomatic UTI. The secondary outcomes are change of MRO status and bowel function, quality of life and cost-effectiveness of probiotics in persons with SCI. The primary outcome will be analysed using survival analysis of factorial groups, with Cox regression modelling to test the effect of each treatment while allowing for the other, assuming no interaction effect. Hazard ratios and Kaplan-Meier survival curves will be used to summarise results. DISCUSSION: If these probiotics are shown to be effective in preventing UTI and MRO colonisation, they would be a very attractive alternative for UTI prophylaxis and for combating the increasing rate of antibiotic resistance after SCI. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry [ ACTRN 12610000512022 ]. Date of registration: 21 June 2010.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Justin</style></label><notes><style face="normal" font="default" size="100%">1471-2490&#xD;Lee, Bonsan Bonne&#xD;Toh, Swee-Ling&#xD;Ryan, Suzanne&#xD;Simpson, Judy M&#xD;Clezy, Kate&#xD;Bossa, Laetitia&#xD;Rice, Scott A&#xD;Marial, Obaydullah&#xD;Weber, Gerard&#xD;Kaur, Jasbeer&#xD;Boswell-Ruys, Claire&#xD;Goodall, Stephen&#xD;Middleton, James&#xD;Tudehope, Mark&#xD;Kotsiou, George&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s12894-016-0136-8.</style></electronic-resource-num></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2056</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">2056</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Little, P.</style></author><author><style face="normal" font="default" size="100%">Moore, M. V.</style></author><author><style face="normal" font="default" size="100%">Turner, S.</style></author><author><style face="normal" font="default" size="100%">Rumsby, K.</style></author><author><style face="normal" font="default" size="100%">Warner, G.</style></author><author><style face="normal" font="default" size="100%">Lowes, J. A.</style></author><author><style face="normal" font="default" size="100%">Smith, H.</style></author><author><style face="normal" font="default" size="100%">Hawke, C.</style></author><author><style face="normal" font="default" size="100%">Leydon, G.</style></author><author><style face="normal" font="default" size="100%">Arscott, A.</style></author><author><style face="normal" font="default" size="100%">Turner, D.</style></author><author><style face="normal" font="default" size="100%">Mullee, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Primary Care Medical Group, Community Clinical Sciences Division, University of Southampton School of Medicine, Southampton SO16 5ST. p.little@soton.ac.uk</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effectiveness of five different approaches in management of urinary tract infection: randomised controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">Bmj</style></secondary-title><short-title><style face="normal" font="default" size="100%">Effectiveness of five different approaches in management of urinary tract infection: randomised controlled trial</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Bmj</style></full-title><abbr-1><style face="normal" font="default" size="100%">BMJ (Clinical research ed.)</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">c199</style></pages><volume><style face="normal" font="default" size="100%">340</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Pamphlets</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Education as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Reagent Strips</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/diagnosis/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb 5</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0959-8138</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To assess the impact of different management strategies in urinary tract infections. DESIGN: Randomised controlled trial. SETTING: Primary care. PARTICIPANTS: 309 non-pregnant women aged 18-70 presenting with suspected urinary tract infection. INTERVENTION: Patients were randomised to five management approaches: empirical antibiotics; empirical delayed (by 48 hours) antibiotics; or targeted antibiotics based on a symptom score (two or more of urine cloudiness, urine smell, nocturia, or dysuria), a dipstick result (nitrite or both leucocytes and blood), or a positive result on midstream urine analysis. Self help advice was controlled in each group. MAIN OUTCOME MEASURES: Symptom severity (days 2 to 4) and duration, and use of antibiotics. RESULTS: Patients had 3.5 days of moderately bad symptoms if they took antibiotics immediately. There were no significant differences in duration or severity of symptoms (mean frequency of symptoms on a 0 to 6 scale: immediate antibiotics 2.15, midstream urine 2.08, dipstick 1.74, symptom score 1.77, delayed antibiotics 2.11; likelihood ratio test for the five groups P=0.177). There were differences in antibiotic use (immediate antibiotics 97%, midstream urine 81%, dipstick 80%, symptom score 90%, delayed antibiotics 77%; P=0.011) and in sending midstream urine samples (immediate antibiotics 23%, midstream urine 89%, dipstick 36%, symptom score 33%, delayed antibiotics 15%; P&lt;0.001). Patients who waited at least 48 hours to start taking antibiotics reconsulted less (hazard ratio 0.57 (95% confidence interval 0.36 to 0.89), P=0.014) but on average had symptoms for 37% longer than those taking immediate antibiotics (incident rate ratio 1.37 (1.11 to 1.68), P=0.003), particularly the midstream urine group (73% longer, 22% to 140%; none of the other groups had more than 22% longer duration). CONCLUSION: All management strategies achieve similar symptom control. There is no advantage in routinely sending midstream urine samples for testing, and antibiotics targeted with dipstick tests with a delayed prescription as backup, or empirical delayed prescription, can help to reduce antibiotic use. STUDY REGISTRATION: National Research Register N0484094184 ISRCTN: 03525333.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Anna</style></label><notes><style face="normal" font="default" size="100%">1756-1833&#xD;Little, P&#xD;Moore, M V&#xD;Turner, S&#xD;Rumsby, K&#xD;Warner, G&#xD;Lowes, J A&#xD;Smith, H&#xD;Hawke, C&#xD;Leydon, G&#xD;Arscott, A&#xD;Turner, D&#xD;Mullee, M&#xD;Comparative Study&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/bmj.c199.</style></electronic-resource-num></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2938</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">2938</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Little, P.</style></author><author><style face="normal" font="default" size="100%">Moore, M. V.</style></author><author><style face="normal" font="default" size="100%">Turner, S.</style></author><author><style face="normal" font="default" size="100%">Rumsby, K.</style></author><author><style face="normal" font="default" size="100%">Warner, G.</style></author><author><style face="normal" font="default" size="100%">Lowes, J. A.</style></author><author><style face="normal" font="default" size="100%">Smith, H.</style></author><author><style face="normal" font="default" size="100%">Hawke, C.</style></author><author><style face="normal" font="default" size="100%">Leydon, G.</style></author><author><style face="normal" font="default" size="100%">Arscott, A.</style></author><author><style face="normal" font="default" size="100%">Turner, D.</style></author><author><style face="normal" font="default" size="100%">Mullee, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Primary Care Medical Group, Community Clinical Sciences Division, University of Southampton School of Medicine, Southampton SO16 5ST. p.little@soton.ac.uk</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effectiveness of five different approaches in management of urinary tract infection: randomised controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">Bmj</style></secondary-title><short-title><style face="normal" font="default" size="100%">Effectiveness of five different approaches in management of urinary tract infection: randomised controlled trial</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Bmj</style></full-title><abbr-1><style face="normal" font="default" size="100%">BMJ (Clinical research ed.)</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">c199</style></pages><volume><style face="normal" font="default" size="100%">340</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Pamphlets</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Education as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Reagent Strips</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/diagnosis/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb 5</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0959-8138</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To assess the impact of different management strategies in urinary tract infections. DESIGN: Randomised controlled trial. SETTING: Primary care. PARTICIPANTS: 309 non-pregnant women aged 18-70 presenting with suspected urinary tract infection. INTERVENTION: Patients were randomised to five management approaches: empirical antibiotics; empirical delayed (by 48 hours) antibiotics; or targeted antibiotics based on a symptom score (two or more of urine cloudiness, urine smell, nocturia, or dysuria), a dipstick result (nitrite or both leucocytes and blood), or a positive result on midstream urine analysis. Self help advice was controlled in each group. MAIN OUTCOME MEASURES: Symptom severity (days 2 to 4) and duration, and use of antibiotics. RESULTS: Patients had 3.5 days of moderately bad symptoms if they took antibiotics immediately. There were no significant differences in duration or severity of symptoms (mean frequency of symptoms on a 0 to 6 scale: immediate antibiotics 2.15, midstream urine 2.08, dipstick 1.74, symptom score 1.77, delayed antibiotics 2.11; likelihood ratio test for the five groups P=0.177). There were differences in antibiotic use (immediate antibiotics 97%, midstream urine 81%, dipstick 80%, symptom score 90%, delayed antibiotics 77%; P=0.011) and in sending midstream urine samples (immediate antibiotics 23%, midstream urine 89%, dipstick 36%, symptom score 33%, delayed antibiotics 15%; P&lt;0.001). Patients who waited at least 48 hours to start taking antibiotics reconsulted less (hazard ratio 0.57 (95% confidence interval 0.36 to 0.89), P=0.014) but on average had symptoms for 37% longer than those taking immediate antibiotics (incident rate ratio 1.37 (1.11 to 1.68), P=0.003), particularly the midstream urine group (73% longer, 22% to 140%; none of the other groups had more than 22% longer duration). CONCLUSION: All management strategies achieve similar symptom control. There is no advantage in routinely sending midstream urine samples for testing, and antibiotics targeted with dipstick tests with a delayed prescription as backup, or empirical delayed prescription, can help to reduce antibiotic use. STUDY REGISTRATION: National Research Register N0484094184 ISRCTN: 03525333.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Justin</style></label><notes><style face="normal" font="default" size="100%">1756-1833&#xD;Little, P&#xD;Moore, M V&#xD;Turner, S&#xD;Rumsby, K&#xD;Warner, G&#xD;Lowes, J A&#xD;Smith, H&#xD;Hawke, C&#xD;Leydon, G&#xD;Arscott, A&#xD;Turner, D&#xD;Mullee, M&#xD;Comparative Study&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/bmj.c199.</style></electronic-resource-num></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2067</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">2067</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lumsden, L.</style></author><author><style face="normal" font="default" size="100%">Hyner, G. C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of an educational intervention on the rate of recurrent urinary tract infections in selected female outpatients</style></title><secondary-title><style face="normal" font="default" size="100%">Women Health</style></secondary-title><short-title><style face="normal" font="default" size="100%">Effects of an educational intervention on the rate of recurrent urinary tract infections in selected female outpatients</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Women Health</style></full-title><abbr-1><style face="normal" font="default" size="100%">Women &amp; health</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">79-86</style></pages><volume><style face="normal" font="default" size="100%">10</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Outpatients</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Education as Topic/*standards</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/epidemiology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Virginia</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1985</style></year><pub-dates><date><style face="normal" font="default" size="100%">Spring</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0363-0242 (Print)&#xD;0363-0242</style></isbn><abstract><style face="normal" font="default" size="100%">This study was designed to prospectively study the effect of health education on the recurrence rate of urinary tract infections in female outpatients. Thirty-four volunteers were randomly assigned to either an experimental education group or a control group. Controls were offered routine patient information provided by practitioners at the outpatient clinic. Members of the experimental group participated in an educational session which addressed urinary tract infections, its risk factors, and behavioral changes which might reduce its recurrence. At follow-up three months after the educational session, the experimental group had a statistically significant (p less than .05) reduction in the recurrence of urinary tract infections.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Anna</style></label><notes><style face="normal" font="default" size="100%">Lumsden, L&#xD;Hyner, G C&#xD;Clinical Trial&#xD;Comparative Study&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;United States</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1300/J013v10n01_06.</style></electronic-resource-num></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2940</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">2940</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lumsden, L.</style></author><author><style face="normal" font="default" size="100%">Hyner, G. C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of an educational intervention on the rate of recurrent urinary tract infections in selected female outpatients</style></title><secondary-title><style face="normal" font="default" size="100%">Women Health</style></secondary-title><short-title><style face="normal" font="default" size="100%">Effects of an educational intervention on the rate of recurrent urinary tract infections in selected female outpatients</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Women Health</style></full-title><abbr-1><style face="normal" font="default" size="100%">Women &amp; health</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">79-86</style></pages><volume><style face="normal" font="default" size="100%">10</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Outpatients</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Education as Topic/*standards</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/epidemiology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Virginia</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1985</style></year><pub-dates><date><style face="normal" font="default" size="100%">Spring</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0363-0242 (Print)&#xD;0363-0242</style></isbn><abstract><style face="normal" font="default" size="100%">This study was designed to prospectively study the effect of health education on the recurrence rate of urinary tract infections in female outpatients. Thirty-four volunteers were randomly assigned to either an experimental education group or a control group. Controls were offered routine patient information provided by practitioners at the outpatient clinic. Members of the experimental group participated in an educational session which addressed urinary tract infections, its risk factors, and behavioral changes which might reduce its recurrence. At follow-up three months after the educational session, the experimental group had a statistically significant (p less than .05) reduction in the recurrence of urinary tract infections.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Justin</style></label><notes><style face="normal" font="default" size="100%">Lumsden, L&#xD;Hyner, G C&#xD;Clinical Trial&#xD;Comparative Study&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;United States</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1300/J013v10n01_06.</style></electronic-resource-num></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2074</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">2074</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Magasi, P.</style></author><author><style face="normal" font="default" size="100%">Panovics, J.</style></author><author><style face="normal" font="default" size="100%">Illes, A.</style></author><author><style face="normal" font="default" size="100%">Nagy, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, Hajnal Imre University School of Medicine, Budapest, Hungary.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Uro-Vaxom and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trial</style></title><secondary-title><style face="normal" font="default" size="100%">Eur Urol</style></secondary-title><short-title><style face="normal" font="default" size="100%">Uro-Vaxom and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trial</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Eur Urol</style></full-title><abbr-1><style face="normal" font="default" size="100%">European urology</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">137-140</style></pages><volume><style face="normal" font="default" size="100%">26</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adjuvants, Immunologic/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Infective Agents, Urinary/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/*drug therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1994</style></year></dates><isbn><style face="normal" font="default" size="100%">0302-2838 (Print)&#xD;0302-2838</style></isbn><abstract><style face="normal" font="default" size="100%">A total of 112 patients with recurrent lower urinary tract infection (UTI) completed the 6-month period of the trial. Patients were treated for 3 months, under double-blind conditions, with one capsule daily of either Uro-Vaxom (UV) or placebo, together with an antibiotic or chemotherapeutic agent when necessary, and observed for a further 3 months. During the 6 months of the trial a significant decrease in the number of recurrences (p &lt; 0.0005) was noted in the UV group as compared to the placebo group. A total of 67.2% of the patients had no recurrences (p &lt; 0.0005). The incidence of bacteriuria (germs &gt; or = 10(5)/ml), dysuria and leukocyturia was significantly reduced. UV was well tolerated, no side effects were recorded during the trial. The drug is a useful adjuvant for the management of UTIs and for the prevention of recurrences.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Anna</style></label><notes><style face="normal" font="default" size="100%">Magasi, P&#xD;Panovics, J&#xD;Illes, A&#xD;Nagy, M&#xD;Clinical Trial&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Switzerland&#xD;Eur Urol. 1994;26(2):137-40.</style></notes><urls></urls></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2941</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">2941</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Magasi, P.</style></author><author><style face="normal" font="default" size="100%">Panovics, J.</style></author><author><style face="normal" font="default" size="100%">Illes, A.</style></author><author><style face="normal" font="default" size="100%">Nagy, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, Hajnal Imre University School of Medicine, Budapest, Hungary.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Uro-Vaxom and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trial</style></title><secondary-title><style face="normal" font="default" size="100%">Eur Urol</style></secondary-title><short-title><style face="normal" font="default" size="100%">Uro-Vaxom and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trial</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Eur Urol</style></full-title><abbr-1><style face="normal" font="default" size="100%">European urology</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">137-140</style></pages><volume><style face="normal" font="default" size="100%">26</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adjuvants, Immunologic/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Infective Agents, Urinary/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/*drug therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1994</style></year></dates><isbn><style face="normal" font="default" size="100%">0302-2838 (Print)&#xD;0302-2838</style></isbn><abstract><style face="normal" font="default" size="100%">A total of 112 patients with recurrent lower urinary tract infection (UTI) completed the 6-month period of the trial. Patients were treated for 3 months, under double-blind conditions, with one capsule daily of either Uro-Vaxom (UV) or placebo, together with an antibiotic or chemotherapeutic agent when necessary, and observed for a further 3 months. During the 6 months of the trial a significant decrease in the number of recurrences (p &lt; 0.0005) was noted in the UV group as compared to the placebo group. A total of 67.2% of the patients had no recurrences (p &lt; 0.0005). The incidence of bacteriuria (germs &gt; or = 10(5)/ml), dysuria and leukocyturia was significantly reduced. UV was well tolerated, no side effects were recorded during the trial. The drug is a useful adjuvant for the management of UTIs and for the prevention of recurrences.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Justin</style></label><notes><style face="normal" font="default" size="100%">Magasi, P&#xD;Panovics, J&#xD;Illes, A&#xD;Nagy, M&#xD;Clinical Trial&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Switzerland&#xD;Eur Urol. 1994;26(2):137-40.</style></notes><urls></urls></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2142</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">2142</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pakzad, M.</style></author><author><style face="normal" font="default" size="100%">Phe, V.</style></author><author><style face="normal" font="default" size="100%">Haslam, C.</style></author><author><style face="normal" font="default" size="100%">Gonzales, G.</style></author><author><style face="normal" font="default" size="100%">Curtis, C.</style></author><author><style face="normal" font="default" size="100%">Porter, B.</style></author><author><style face="normal" font="default" size="100%">Chataway, J.</style></author><author><style face="normal" font="default" size="100%">Panicker, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">An open label feasibility study evaluating D-Mannose for the prevention of urinary tract infections in patients with multiple sclerosis</style></title><secondary-title><style face="normal" font="default" size="100%">Multiple sclerosis (Houndmills, Basingstoke, England)</style></secondary-title><short-title><style face="normal" font="default" size="100%">An open label feasibility study evaluating D-Mannose for the prevention of urinary tract infections in patients with multiple sclerosis</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Multiple sclerosis (Houndmills, Basingstoke, England)</style></full-title></periodical><pages><style face="normal" font="default" size="100%">815‐816</style></pages><volume><style face="normal" font="default" size="100%">Conference: 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, ECTRIMS 2016. United Kingdom. Conference Start: 20160914. Conference End: 20160917. 22</style></volume><keywords><keyword><style face="normal" font="default" size="100%">*feasibility study</style></keyword><keyword><style face="normal" font="default" size="100%">*mannose</style></keyword><keyword><style face="normal" font="default" size="100%">*multiple sclerosis</style></keyword><keyword><style face="normal" font="default" size="100%">*urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">Antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">Antibiotic resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Catheter</style></keyword><keyword><style face="normal" font="default" size="100%">Comparative effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword><keyword><style face="normal" font="default" size="100%">Human tissue</style></keyword><keyword><style face="normal" font="default" size="100%">Major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle aged</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Prescription</style></keyword><keyword><style face="normal" font="default" size="100%">Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">Safety</style></keyword><keyword><style face="normal" font="default" size="100%">Side effect</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Introduction: Recurrent urinary tract infections (rUTIs) are a significant problem in people with multiple sclerosis (PwMS). Current therapeutic options are limited. D‐mannose is a natural food supplement which has been shown to prevent UTIs in women, however benefits in PwMS are unknown. This study assessed D‐Mannose feasibility in PwMS reporting rUTIs. Methods: A prospective single centre, open‐label, feasibility study with PwMS suffering rUTIs (&gt;3/year or &gt;2 in preceding 6 months). Participants took D‐mannose‐powder 1.5 grams bd (16‐ weeks) and monitored suspected UTIs using urine dipsticks. Diaries were used to record compliance, number of antibiotic prescriptions, dipstick results cultures. Results: 22 PwMS (18 female, 4 men), median age 50 years (46‐ 59) were enrolled. 61 suspected‐UTI episodes were recorded; 19/61 (31.1%) were confirmed UTIs; 29 (47.5%) antibiotic prescriptions were written. Number of proven‐UTIs decreased both in catheter users and non‐users (p&lt; 0.01). No side effects or adverse effects were reported. Discussion: This study demonstrates the feasibility of using D‐mannose in PwMS experiencing recurrent UTIs and selfmonitoring for infections, without any safety concerns. The use of D‐mannose was associated with a reduction in the number of UTIs. As the study was designed to evaluate only feasibility, no conclusions could be drawn about efficacy, however the results are encouraging and clearly, a randomized controlled study designed to evaluate efficacy is required. The emerging global problem of antimicrobial resistance makes agents such as D‐Mannose a particularly attractive option for the prophylaxis against rUTIs.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Anna</style></label><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01212273/full</style></url></related-urls></urls></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2945</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">2945</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pakzad, M.</style></author><author><style face="normal" font="default" size="100%">Phe, V.</style></author><author><style face="normal" font="default" size="100%">Haslam, C.</style></author><author><style face="normal" font="default" size="100%">Gonzales, G.</style></author><author><style face="normal" font="default" size="100%">Curtis, C.</style></author><author><style face="normal" font="default" size="100%">Porter, B.</style></author><author><style face="normal" font="default" size="100%">Chataway, J.</style></author><author><style face="normal" font="default" size="100%">Panicker, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">An open label feasibility study evaluating D-Mannose for the prevention of urinary tract infections in patients with multiple sclerosis</style></title><secondary-title><style face="normal" font="default" size="100%">Multiple sclerosis (Houndmills, Basingstoke, England)</style></secondary-title><short-title><style face="normal" font="default" size="100%">An open label feasibility study evaluating D-Mannose for the prevention of urinary tract infections in patients with multiple sclerosis</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Multiple sclerosis (Houndmills, Basingstoke, England)</style></full-title></periodical><pages><style face="normal" font="default" size="100%">815‐816</style></pages><volume><style face="normal" font="default" size="100%">Conference: 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, ECTRIMS 2016. United Kingdom. Conference Start: 20160914. Conference End: 20160917. 22</style></volume><keywords><keyword><style face="normal" font="default" size="100%">*feasibility study</style></keyword><keyword><style face="normal" font="default" size="100%">*mannose</style></keyword><keyword><style face="normal" font="default" size="100%">*multiple sclerosis</style></keyword><keyword><style face="normal" font="default" size="100%">*urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">Antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">Antibiotic resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Catheter</style></keyword><keyword><style face="normal" font="default" size="100%">Comparative effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword><keyword><style face="normal" font="default" size="100%">Human tissue</style></keyword><keyword><style face="normal" font="default" size="100%">Major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle aged</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Prescription</style></keyword><keyword><style face="normal" font="default" size="100%">Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">Safety</style></keyword><keyword><style face="normal" font="default" size="100%">Side effect</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Introduction: Recurrent urinary tract infections (rUTIs) are a significant problem in people with multiple sclerosis (PwMS). Current therapeutic options are limited. D‐mannose is a natural food supplement which has been shown to prevent UTIs in women, however benefits in PwMS are unknown. This study assessed D‐Mannose feasibility in PwMS reporting rUTIs. Methods: A prospective single centre, open‐label, feasibility study with PwMS suffering rUTIs (&gt;3/year or &gt;2 in preceding 6 months). Participants took D‐mannose‐powder 1.5 grams bd (16‐ weeks) and monitored suspected UTIs using urine dipsticks. Diaries were used to record compliance, number of antibiotic prescriptions, dipstick results cultures. Results: 22 PwMS (18 female, 4 men), median age 50 years (46‐ 59) were enrolled. 61 suspected‐UTI episodes were recorded; 19/61 (31.1%) were confirmed UTIs; 29 (47.5%) antibiotic prescriptions were written. Number of proven‐UTIs decreased both in catheter users and non‐users (p&lt; 0.01). No side effects or adverse effects were reported. Discussion: This study demonstrates the feasibility of using D‐mannose in PwMS experiencing recurrent UTIs and selfmonitoring for infections, without any safety concerns. The use of D‐mannose was associated with a reduction in the number of UTIs. As the study was designed to evaluate only feasibility, no conclusions could be drawn about efficacy, however the results are encouraging and clearly, a randomized controlled study designed to evaluate efficacy is required. The emerging global problem of antimicrobial resistance makes agents such as D‐Mannose a particularly attractive option for the prophylaxis against rUTIs.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Justin</style></label><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01212273/full</style></url></related-urls></urls></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2208</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">2208</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Salinas-Casado, J.</style></author><author><style face="normal" font="default" size="100%">Mendez-Rubio, S.</style></author><author><style face="normal" font="default" size="100%">Esteban-Fuertes, M.</style></author><author><style face="normal" font="default" size="100%">Gomez-Rodriguez, A.</style></author><author><style face="normal" font="default" size="100%">Virseda-Chamorro, M.</style></author><author><style face="normal" font="default" size="100%">Lujan-Galan, M.</style></author><author><style face="normal" font="default" size="100%">Rituman, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Servicio de Urologia. Hospital Clinico San Carlos. Madrid. Espana.&#xD;Servicio de Urologia. Hospital Universitario Sanitas La Moraleja. Madrid. Espana.&#xD;Servicio de Urologia. Hospital Nacional de Paraplejicos de Toledo. Toledo. Espana.&#xD;Servicio de Urologia. Complejo Hospitalario de Toledo. Toledo. Espana.&#xD;Servicio de Urologia. Hospital Universitario de Parla. Madrid. Espana.</style></auth-address><titles><title><style face="normal" font="default" size="100%">[Efficacy and safety of D-mannose (2 g), 24h prolonged release, associated with Proanthocyanidin (PAC), versus isolate PAC, in the management of a series of women with recurrent urinary infections.]</style></title><secondary-title><style face="normal" font="default" size="100%">Arch Esp Urol</style></secondary-title><short-title><style face="normal" font="default" size="100%">[Efficacy and safety of D-mannose (2 g), 24h prolonged release, associated with Proanthocyanidin (PAC), versus isolate PAC, in the management of a series of women with recurrent urinary infections.]</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Arch Esp Urol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Archivos espanoles de urologia</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">169-177</style></pages><volume><style face="normal" font="default" size="100%">71</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Delayed-Action Preparations</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mannose/*administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidins/*administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/*drug therapy/*prevention &amp; control</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0004-0614 (Print)&#xD;0004-0614</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To compare the efficacy and safety of dietary supplement &quot;Manosar(R)&quot; composed of D-mannose (2 g), 24 h prolonged release, associated with Proanthocyanidin (PAC) (140 mg), ursolic acid (7.98 mg), A, C, and D vitamins and the oligoelement zinc, versus 240 mg of PAC in recurrent urinary tract infections (UTI), for a designed follow-up of 24 weeks, in women. METHODS: A multicenter randomized experimental double-blind study was carried out. The study was approved by review board of &quot;Complejo Hospitalario de Toledo&quot; (Spain), and all patients gave informed consent. A total of 150 women with non complicated UTI were screened for participation. Valid data was obtained from 93, with mean age of 48 years. Fortyfour patients were assigned to the Manosar(R) group and 51 patients to the PAC group. Patients were followed during six months. A previous UTI was defined based on a combination of symptoms and a positive reactive urine trip. Confirmation of a new UTI was based on symptoms, reactive urine strip and urine culture. RESULTS: Thirty-three patients (35%) had an UTI during the six months follow-up. The percentage of UTI of the Manosar(R) group during this period was 24%, while the percentage of the PAC group was 45% (p&lt;0.05). The disease-free time for the Manosar(R) group was 95 days, while this time was 79 days for the PAC group. The incidence of side effects was low. Diarrhea was the most frequent side-effect in both groups. CONCLUSION: Manosar(R) (oral once a day) is more effective than single dose PAC (240 mg daily orally) to prevent recurrent UTI in women.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Anna</style></label><notes><style face="normal" font="default" size="100%">Salinas-Casado, Jesus&#xD;Mendez-Rubio, Santiago&#xD;Esteban-Fuertes, Manuel&#xD;Gomez-Rodriguez, Antonio&#xD;Virseda-Chamorro, Miguel&#xD;Lujan-Galan, Marcos&#xD;Rituman, Grupo&#xD;Comparative Study&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Spain&#xD;Arch Esp Urol. 2018 Mar;71(2):169-177.</style></notes><urls></urls></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2949</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">2949</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Salinas-Casado, J.</style></author><author><style face="normal" font="default" size="100%">Mendez-Rubio, S.</style></author><author><style face="normal" font="default" size="100%">Esteban-Fuertes, M.</style></author><author><style face="normal" font="default" size="100%">Gomez-Rodriguez, A.</style></author><author><style face="normal" font="default" size="100%">Virseda-Chamorro, M.</style></author><author><style face="normal" font="default" size="100%">Lujan-Galan, M.</style></author><author><style face="normal" font="default" size="100%">Rituman, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Servicio de Urologia. Hospital Clinico San Carlos. Madrid. Espana.&#xD;Servicio de Urologia. Hospital Universitario Sanitas La Moraleja. Madrid. Espana.&#xD;Servicio de Urologia. Hospital Nacional de Paraplejicos de Toledo. Toledo. Espana.&#xD;Servicio de Urologia. Complejo Hospitalario de Toledo. Toledo. Espana.&#xD;Servicio de Urologia. Hospital Universitario de Parla. Madrid. Espana.</style></auth-address><titles><title><style face="normal" font="default" size="100%">[Efficacy and safety of D-mannose (2 g), 24h prolonged release, associated with Proanthocyanidin (PAC), versus isolate PAC, in the management of a series of women with recurrent urinary infections.]</style></title><secondary-title><style face="normal" font="default" size="100%">Arch Esp Urol</style></secondary-title><short-title><style face="normal" font="default" size="100%">[Efficacy and safety of D-mannose (2 g), 24h prolonged release, associated with Proanthocyanidin (PAC), versus isolate PAC, in the management of a series of women with recurrent urinary infections.]</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Arch Esp Urol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Archivos espanoles de urologia</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">169-177</style></pages><volume><style face="normal" font="default" size="100%">71</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Delayed-Action Preparations</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mannose/*administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidins/*administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/*drug therapy/*prevention &amp; control</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0004-0614 (Print)&#xD;0004-0614</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To compare the efficacy and safety of dietary supplement &quot;Manosar(R)&quot; composed of D-mannose (2 g), 24 h prolonged release, associated with Proanthocyanidin (PAC) (140 mg), ursolic acid (7.98 mg), A, C, and D vitamins and the oligoelement zinc, versus 240 mg of PAC in recurrent urinary tract infections (UTI), for a designed follow-up of 24 weeks, in women. METHODS: A multicenter randomized experimental double-blind study was carried out. The study was approved by review board of &quot;Complejo Hospitalario de Toledo&quot; (Spain), and all patients gave informed consent. A total of 150 women with non complicated UTI were screened for participation. Valid data was obtained from 93, with mean age of 48 years. Fortyfour patients were assigned to the Manosar(R) group and 51 patients to the PAC group. Patients were followed during six months. A previous UTI was defined based on a combination of symptoms and a positive reactive urine trip. Confirmation of a new UTI was based on symptoms, reactive urine strip and urine culture. RESULTS: Thirty-three patients (35%) had an UTI during the six months follow-up. The percentage of UTI of the Manosar(R) group during this period was 24%, while the percentage of the PAC group was 45% (p&lt;0.05). The disease-free time for the Manosar(R) group was 95 days, while this time was 79 days for the PAC group. The incidence of side effects was low. Diarrhea was the most frequent side-effect in both groups. CONCLUSION: Manosar(R) (oral once a day) is more effective than single dose PAC (240 mg daily orally) to prevent recurrent UTI in women.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Justin</style></label><notes><style face="normal" font="default" size="100%">Salinas-Casado, Jesus&#xD;Mendez-Rubio, Santiago&#xD;Esteban-Fuertes, Manuel&#xD;Gomez-Rodriguez, Antonio&#xD;Virseda-Chamorro, Miguel&#xD;Lujan-Galan, Marcos&#xD;Rituman, Grupo&#xD;Comparative Study&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Spain&#xD;Arch Esp Urol. 2018 Mar;71(2):169-177.</style></notes><urls></urls></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2254</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">2254</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Skerk, V.</style></author><author><style face="normal" font="default" size="100%">Ferincevic, R.</style></author><author><style face="normal" font="default" size="100%">Markotic, A.</style></author><author><style face="normal" font="default" size="100%">Andrasevic, S.</style></author><author><style face="normal" font="default" size="100%">Milosevic, V.</style></author><author><style face="normal" font="default" size="100%">Vargovic, M.</style></author><author><style face="normal" font="default" size="100%">Pasini, M.</style></author><author><style face="normal" font="default" size="100%">Turcic, P.</style></author><author><style face="normal" font="default" size="100%">Begovac, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">V. Škerk, Klinika za Infektivne Bolesti Dr. Fran Mihaljević, Zagreb, Croatia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Research on the efficacy of prophylactic use of Acidosalus probiotic in women with recurrent cystitis</style></title><secondary-title><style face="normal" font="default" size="100%">Infektoloski glasnik</style></secondary-title><short-title><style face="normal" font="default" size="100%">Research on the efficacy of prophylactic use of Acidosalus probiotic in women with recurrent cystitis</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infektoloski glasnik</style></full-title></periodical><pages><style face="normal" font="default" size="100%">21‐25</style></pages><volume><style face="normal" font="default" size="100%">30</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">*acidosalus/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*acidosalus/po [Oral Drug Administration]</style></keyword><keyword><style face="normal" font="default" size="100%">*acidosalus/va [Intravaginal Drug Administration]</style></keyword><keyword><style face="normal" font="default" size="100%">*cystitis/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*cystitis/pc [Prevention]</style></keyword><keyword><style face="normal" font="default" size="100%">*probiotic agent/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*probiotic agent/po [Oral Drug Administration]</style></keyword><keyword><style face="normal" font="default" size="100%">*probiotic agent/va [Intravaginal Drug Administration]</style></keyword><keyword><style face="normal" font="default" size="100%">*recurrent cystitis/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*recurrent cystitis/pc [Prevention]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Antibiotic agent/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Article</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical research</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Follow up</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword><keyword><style face="normal" font="default" size="100%">Major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">Prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment duration</style></keyword><keyword><style face="normal" font="default" size="100%">Unclassified drug</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><isbn><style face="normal" font="default" size="100%">1331-2820</style></isbn><abstract><style face="normal" font="default" size="100%">The aim of this prospective research was to investigate the efficacy of prophylactic use of probiotic Acidosalus in women with recurrent cystitis. Acidosalus is a unique combination of Lactobacillus acidophilus, Lactobacillus rhamnosus and bifidobacteria in high therapeutic concentrations of live bacteria ready for multiplication. It consists of group B vitamins, folic acid, highly soluble lactates, potassium, iron, phosphorus, and has the possibility to produce antimicrobial substances ‐ lactic and acetic acid, diacetyl, lactocidine, acidophilucin, acidocin and acidophylin. The research was conducted at the Outpatient Department for Urogenital Infections of the University Hospital for Infectious Diseases &quot;Dr. Fran Mihaljevic &quot; in Zagreb in the period between 01.01.2006. until 31.12.2009. We investigated 117 patients aged between 18 and 65 years with diagnosed recurrent cystitis ‐ more than two episodes of cystitis in the past 6, i.e. more than three episodes in the past 12 months. The inclusion criteria were as follows: presence of symptoms of lower urinary tract infection (dysuria, polakisuria, urgency), identical microbiological finding of cervical swab and urinary culture, leukocyturia, ultrasound excluded urinary tract abnormality. All patients received adequate antimicrobial therapy for 7 days and then were randomly divided into two groups. One group received Acidosalus probiotic as a prophylaxis immediately after the end of antimicrobial therapy ‐ and at least three months continuously received Acidosalus orally with simultaneous vaginal administration of Acidosalus vaginalettes for at least 7 days. Planned duration of prophylaxis was three months. Follow up visit performed 1‐2 weeks after completion of seven day course of antimicrobial therapy showed that all patients were clinically and bacteriologically cured. Until the follow up visit three months after completed 7‐day antimicrobial therapy, recurrent episodes of cystitis were recorded in 3 (5,4 %) out of a total of 56 women who received probiotic prophylaxis and in 11 (18,3 %) out of a total of 61 women who did not receive probiotic prophylaxis. Three months after completed 7‐day course of antimicrobial therapy, uropathogen bacteria were more often detected in vagina of women who did not receive probiotic prophylaxis (in 44 out of a total of 50 monitored patients ‐ 88 %) than in women who did not receive probiotic prophylaxis (in 18 out of a total of 53 patients ‐ 34 %). The results of this study have shown that prophylactic use of mixed probiotic culture present in medicinal product Acidosalus in women with recurrent urinary tract infections is efficient and safe. We would like to stress the importance of simultaneous oral and vaginal application, by which we achieve regeneration and improved function of autochthonous intestinal and vaginal microflora, reduce a reservoir of uropathogen bacteria in intestines and boost immunity in general.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Anna</style></label><notes><style face="normal" font="default" size="100%">L359858084&#xD;2010-11-09&#xD;2010-11-15</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00803838/full</style></url></related-urls></urls></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2952</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">2952</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Skerk, V.</style></author><author><style face="normal" font="default" size="100%">Ferincevic, R.</style></author><author><style face="normal" font="default" size="100%">Markotic, A.</style></author><author><style face="normal" font="default" size="100%">Andrasevic, S.</style></author><author><style face="normal" font="default" size="100%">Milosevic, V.</style></author><author><style face="normal" font="default" size="100%">Vargovic, M.</style></author><author><style face="normal" font="default" size="100%">Pasini, M.</style></author><author><style face="normal" font="default" size="100%">Turcic, P.</style></author><author><style face="normal" font="default" size="100%">Begovac, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">V. Škerk, Klinika za Infektivne Bolesti Dr. Fran Mihaljević, Zagreb, Croatia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Research on the efficacy of prophylactic use of Acidosalus probiotic in women with recurrent cystitis</style></title><secondary-title><style face="normal" font="default" size="100%">Infektoloski glasnik</style></secondary-title><short-title><style face="normal" font="default" size="100%">Research on the efficacy of prophylactic use of Acidosalus probiotic in women with recurrent cystitis</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infektoloski glasnik</style></full-title></periodical><pages><style face="normal" font="default" size="100%">21‐25</style></pages><volume><style face="normal" font="default" size="100%">30</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">*acidosalus/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*acidosalus/po [Oral Drug Administration]</style></keyword><keyword><style face="normal" font="default" size="100%">*acidosalus/va [Intravaginal Drug Administration]</style></keyword><keyword><style face="normal" font="default" size="100%">*cystitis/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*cystitis/pc [Prevention]</style></keyword><keyword><style face="normal" font="default" size="100%">*probiotic agent/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*probiotic agent/po [Oral Drug Administration]</style></keyword><keyword><style face="normal" font="default" size="100%">*probiotic agent/va [Intravaginal Drug Administration]</style></keyword><keyword><style face="normal" font="default" size="100%">*recurrent cystitis/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*recurrent cystitis/pc [Prevention]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Antibiotic agent/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Article</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical research</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Follow up</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword><keyword><style face="normal" font="default" size="100%">Major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">Prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment duration</style></keyword><keyword><style face="normal" font="default" size="100%">Unclassified drug</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><isbn><style face="normal" font="default" size="100%">1331-2820</style></isbn><abstract><style face="normal" font="default" size="100%">The aim of this prospective research was to investigate the efficacy of prophylactic use of probiotic Acidosalus in women with recurrent cystitis. Acidosalus is a unique combination of Lactobacillus acidophilus, Lactobacillus rhamnosus and bifidobacteria in high therapeutic concentrations of live bacteria ready for multiplication. It consists of group B vitamins, folic acid, highly soluble lactates, potassium, iron, phosphorus, and has the possibility to produce antimicrobial substances ‐ lactic and acetic acid, diacetyl, lactocidine, acidophilucin, acidocin and acidophylin. The research was conducted at the Outpatient Department for Urogenital Infections of the University Hospital for Infectious Diseases &quot;Dr. Fran Mihaljevic &quot; in Zagreb in the period between 01.01.2006. until 31.12.2009. We investigated 117 patients aged between 18 and 65 years with diagnosed recurrent cystitis ‐ more than two episodes of cystitis in the past 6, i.e. more than three episodes in the past 12 months. The inclusion criteria were as follows: presence of symptoms of lower urinary tract infection (dysuria, polakisuria, urgency), identical microbiological finding of cervical swab and urinary culture, leukocyturia, ultrasound excluded urinary tract abnormality. All patients received adequate antimicrobial therapy for 7 days and then were randomly divided into two groups. One group received Acidosalus probiotic as a prophylaxis immediately after the end of antimicrobial therapy ‐ and at least three months continuously received Acidosalus orally with simultaneous vaginal administration of Acidosalus vaginalettes for at least 7 days. Planned duration of prophylaxis was three months. Follow up visit performed 1‐2 weeks after completion of seven day course of antimicrobial therapy showed that all patients were clinically and bacteriologically cured. Until the follow up visit three months after completed 7‐day antimicrobial therapy, recurrent episodes of cystitis were recorded in 3 (5,4 %) out of a total of 56 women who received probiotic prophylaxis and in 11 (18,3 %) out of a total of 61 women who did not receive probiotic prophylaxis. Three months after completed 7‐day course of antimicrobial therapy, uropathogen bacteria were more often detected in vagina of women who did not receive probiotic prophylaxis (in 44 out of a total of 50 monitored patients ‐ 88 %) than in women who did not receive probiotic prophylaxis (in 18 out of a total of 53 patients ‐ 34 %). The results of this study have shown that prophylactic use of mixed probiotic culture present in medicinal product Acidosalus in women with recurrent urinary tract infections is efficient and safe. We would like to stress the importance of simultaneous oral and vaginal application, by which we achieve regeneration and improved function of autochthonous intestinal and vaginal microflora, reduce a reservoir of uropathogen bacteria in intestines and boost immunity in general.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Justin</style></label><notes><style face="normal" font="default" size="100%">L359858084&#xD;2010-11-09&#xD;2010-11-15</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00803838/full</style></url></related-urls></urls></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2300</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">2300</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vecchio, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M. Vecchio, Danone Research, Palaiseau, Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">Increased water intake prevents cystitis in premenopausal women: A randomized controlled study</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Gynecology and Obstetrics</style></secondary-title><short-title><style face="normal" font="default" size="100%">Increased water intake prevents cystitis in premenopausal women: A randomized controlled study</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Gynecology and Obstetrics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">313-314</style></pages><volume><style face="normal" font="default" size="100%">143</style></volume><keywords><keyword><style face="normal" font="default" size="100%">antiinfective agent</style></keyword><keyword><style face="normal" font="default" size="100%">water</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">comparative effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">fluid intake</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">human tissue</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">outcome assessment</style></keyword><keyword><style face="normal" font="default" size="100%">premenopause</style></keyword><keyword><style face="normal" font="default" size="100%">quality of life</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">urine volume</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><isbn><style face="normal" font="default" size="100%">1879-3479</style></isbn><abstract><style face="normal" font="default" size="100%">Objectives: As a preventive strategy, clinicians recommend water to women suffering from recurrent acute uncomplicated cystitis (rAUC), however clinical data to support this recommendation are sparse. The aim of this study was to assess the efficacy of increased daily water intake on the frequency of rAUC in women. Method: 140 healthy premenopausal women drinking less than 1.5 liters (L) of total fluid daily and suffering from rAUC (≥3 episodes in the past year) were randomly assigned to increase their daily water intake by 1.5 L (water group) or to continue their habitual fluid intake (control group), for 12 months. Assessments of daily fluid intake, urine parameters, and the quality of life SF-12v2 survey was performed at baseline, 6 and 12-month clinical visits. The primary outcome was frequency of symptomatic rAUC episodes over 12 months. Results: Between baseline and the 12 month follow-up, the water group, compared to the control group, increased mean total fluid intake (1.65 vs. 0.03 L/day) and urine volume (1.40 vs. 0.04 L/day). The mean number of rAUC episodes in the water group was significantly less than in the control group (1.6 vs.3.1; product effect ratio 0.52 (95% CI, 0.46-0.60) p&lt;0.001). The mean number of antimicrobial regimens used to treat AUC events was 1.8 in the water group vs. 3.5 in the control group (product effect ratio 0.53 (0.45-0.61) p&lt;0.001). Increased daily fluid intake did not impact quality of life. Conclusions: Our results are the first to provide clinical evidence that increased water intake is a preventive and effective antimicrobial-sparing strategy for reducing AUC frequency and that does not negatively impact the quality of life of women with rACU.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Anna</style></label><notes><style face="normal" font="default" size="100%">L624606608&#xD;2018-11-01</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L624606608</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1002/ijgo.12582</style></url></related-urls></urls></record><record><database name="UTI management Title abstract disputes resolved.enl" path="D:\Users\Connor\Downloads\UTI management Title abstract disputes resolved.enl">UTI management Title abstract disputes resolved.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2959</rec-number><foreign-keys><key app="EN" db-id="dd20ze5xq9dwdaeptesvrz0zfffw22wep2p2">2959</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vecchio, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M. Vecchio, Danone Research, Palaiseau, Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">Increased water intake prevents cystitis in premenopausal women: A randomized controlled study</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Gynecology and Obstetrics</style></secondary-title><short-title><style face="normal" font="default" size="100%">Increased water intake prevents cystitis in premenopausal women: A randomized controlled study</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Gynecology and Obstetrics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">313-314</style></pages><volume><style face="normal" font="default" size="100%">143</style></volume><keywords><keyword><style face="normal" font="default" size="100%">antiinfective agent</style></keyword><keyword><style face="normal" font="default" size="100%">water</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">comparative effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">fluid intake</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">human tissue</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">outcome assessment</style></keyword><keyword><style face="normal" font="default" size="100%">premenopause</style></keyword><keyword><style face="normal" font="default" size="100%">quality of life</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">urine volume</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><isbn><style face="normal" font="default" size="100%">1879-3479</style></isbn><abstract><style face="normal" font="default" size="100%">Objectives: As a preventive strategy, clinicians recommend water to women suffering from recurrent acute uncomplicated cystitis (rAUC), however clinical data to support this recommendation are sparse. The aim of this study was to assess the efficacy of increased daily water intake on the frequency of rAUC in women. Method: 140 healthy premenopausal women drinking less than 1.5 liters (L) of total fluid daily and suffering from rAUC (≥3 episodes in the past year) were randomly assigned to increase their daily water intake by 1.5 L (water group) or to continue their habitual fluid intake (control group), for 12 months. Assessments of daily fluid intake, urine parameters, and the quality of life SF-12v2 survey was performed at baseline, 6 and 12-month clinical visits. The primary outcome was frequency of symptomatic rAUC episodes over 12 months. Results: Between baseline and the 12 month follow-up, the water group, compared to the control group, increased mean total fluid intake (1.65 vs. 0.03 L/day) and urine volume (1.40 vs. 0.04 L/day). The mean number of rAUC episodes in the water group was significantly less than in the control group (1.6 vs.3.1; product effect ratio 0.52 (95% CI, 0.46-0.60) p&lt;0.001). The mean number of antimicrobial regimens used to treat AUC events was 1.8 in the water group vs. 3.5 in the control group (product effect ratio 0.53 (0.45-0.61) p&lt;0.001). Increased daily fluid intake did not impact quality of life. Conclusions: Our results are the first to provide clinical evidence that increased water intake is a preventive and effective antimicrobial-sparing strategy for reducing AUC frequency and that does not negatively impact the quality of life of women with rACU.</style></abstract><label><style face="normal" font="default" size="100%">Yes - Justin</style></label><notes><style face="normal" font="default" size="100%">L624606608&#xD;2018-11-01</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L624606608</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1002/ijgo.12582</style></url></related-urls></urls></record></records></xml>